Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Parkinson's Disease

  Free Subscription


Articles published in Mov Disord

Retrieve available abstracts of 494 articles:
HTML format
Text format



Single Articles


    December 2017
  1. PICCONI B, Hernandez LF, Obeso JA, Calabresi P, et al
    Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias.
    Mov Disord. 2017 Dec 8. doi: 10.1002/mds.27261.
    PubMed     Text format     Abstract available


  2. GOLDMAN JG, Andrews H, Amara A, Naito A, et al
    Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27232.
    PubMed     Text format     Abstract available


  3. KIEBURTZ K, Katz R, Olanow CW
    New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27220.
    PubMed     Text format    


  4. FERNANDES HJR
    Beyond the lysosome: Cholesterol role on endoplasmic reticulum and lipid droplets in Parkinson's disease.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27249.
    PubMed     Text format    


  5. PADMANABHAN S, Burke RE
    Induction of axon growth in the adult brain: A new approach to restoration in Parkinson's disease.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27209.
    PubMed     Text format    


    November 2017
  6. LOZANO CS, Tam J, Lozano AM
    The changing landscape of surgery for Parkinson's Disease.
    Mov Disord. 2017 Nov 30. doi: 10.1002/mds.27228.
    PubMed     Text format     Abstract available


  7. BHATIA KP, Bain P, Bajaj N, Elble RJ, et al
    Consensus Statement on the classification of tremors, from the task force on tremor of the International Parkinson and Movement Disorder Society.
    Mov Disord. 2017 Nov 30. doi: 10.1002/mds.27121.
    PubMed     Text format     Abstract available


  8. SVENSSON E, Henderson VW, Szepligeti S, Stokholm MG, et al
    Tonsillectomy and risk of Parkinson's disease: A danish nationwide population-based cohort study.
    Mov Disord. 2017 Nov 29. doi: 10.1002/mds.27253.
    PubMed     Text format     Abstract available


  9. BUARD I, Sciacca DM, Martin CS, Rogers S, et al
    Transcranial magnetic stimulation does not improve mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2017 Nov 27. doi: 10.1002/mds.27246.
    PubMed     Text format    


  10. TROPEA TF, Xie SX, Rick J, Chahine LM, et al
    APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27204.
    PubMed     Text format     Abstract available


  11. KOHSAKA M, Oeda T, Umemura A, Tomita S, et al
    Oxybuprocaine for apraxia of lid opening in Parkinson's disease: A placebo-controlled pilot trial.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27243.
    PubMed     Text format    


  12. SKORVANEK M, Goldman JG, Jahanshahi M, Marras C, et al
    Global scales for cognitive screening in Parkinson's disease: Critique and recommendations.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27233.
    PubMed     Text format     Abstract available


  13. KULIKOVSKAJA L, Seibler P
    Dopamine oxidation mediates a time-dependent pathological cascade in Parkinson's disease.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27262.
    PubMed     Text format    


  14. STEIGERWALD F, Timmermann L, Kuhn A, Schnitzler A, et al
    Pulse duration settings in subthalamic stimulation for Parkinson's disease.
    Mov Disord. 2017 Nov 22. doi: 10.1002/mds.27238.
    PubMed     Text format     Abstract available


  15. POCHARD C, Leclair-Visonneau L, Coron E, Neunlist M, et al
    Cyclooxygenase 2 is upregulated in the gastrointestinal tract in Parkinson's disease.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27237.
    PubMed     Text format    


  16. WEAVER FM, Stroupe KT, Smith B, Gonzalez B, et al
    Survival in patients with Parkinson's disease after deep brain stimulation or medical management.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27235.
    PubMed     Text format     Abstract available


  17. DAFSARI HS, Reker P, Stalinski L, Silverdale M, et al
    Quality of life outcomes after subthalamic stimulation in Parkinson's disease depends on age.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27222.
    PubMed     Text format     Abstract available


  18. SYRKIN-NIKOLAU J, Neuville R, O'Day J, Anidi C, et al
    Coordinated reset vibrotactile stimulation shows prolonged improvement in Parkinson's disease.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27223.
    PubMed     Text format    


  19. ELAHI E
    PTRHD1 and possibly ADORA1 mutations contribute to Parkinsonism with intellectual disability.
    Mov Disord. 2017 Nov 16. doi: 10.1002/mds.27126.
    PubMed     Text format    


  20. HELMICH RC
    The cerebral basis of Parkinsonian tremor: A network perspective.
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27224.
    PubMed     Text format     Abstract available


  21. GOETZ CG
    Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years?
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27214.
    PubMed     Text format    


  22. ARNALDI D, De Carli F, Fama F, Brugnolo A, et al
    Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers.
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27190.
    PubMed     Text format     Abstract available


  23. SCHNEIDER SA, Alcalay RN
    Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
    Mov Disord. 2017;32:1504-1523.
    PubMed     Text format     Abstract available


  24. SCHAPIRA AH
    What would James Parkinson think? A virtual dialogue on factors influencing the development of Parkinson's disease.
    Mov Disord. 2017;32:1499-1500.
    PubMed     Text format    


    October 2017
  25. SOHAIL S, Yu L, Schneider JA, Bennett DA, et al
    Sleep fragmentation and Parkinson's disease pathology in older adults without Parkinson's disease.
    Mov Disord. 2017 Oct 30. doi: 10.1002/mds.27200.
    PubMed     Text format     Abstract available


  26. LI W, Lao-Kaim NP, Roussakis AA, Martin-Bastida A, et al
    11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study.
    Mov Disord. 2017 Oct 30. doi: 10.1002/mds.27183.
    PubMed     Text format     Abstract available


  27. METEREAU E, Beaudoin-Gobert M, Duperrier S, Thobois S, et al
    Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey.
    Mov Disord. 2017 Oct 27. doi: 10.1002/mds.27201.
    PubMed     Text format     Abstract available


  28. FASANO A, Canning CG, Hausdorff JM, Lord S, et al
    Falls in Parkinson's disease: A complex and evolving picture.
    Mov Disord. 2017 Oct 25. doi: 10.1002/mds.27195.
    PubMed     Text format     Abstract available


  29. WEINTRAUB D, Chahine LM, Hawkins KA, Siderowf A, et al
    Cognition and the course of prodromal Parkinson's disease.
    Mov Disord. 2017 Oct 24. doi: 10.1002/mds.27189.
    PubMed     Text format     Abstract available


  30. FENGLER S, Liepelt-Scarfone I, Brockmann K, Schaffer E, et al
    Cognitive changes in prodromal Parkinson's disease: A review.
    Mov Disord. 2017 Oct 5. doi: 10.1002/mds.27135.
    PubMed     Text format     Abstract available


  31. ASCHERIO A, Schwarzschild MA
    Dietary antioxidants and Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27194.
    PubMed     Text format    


  32. SAEED U, Masellis M
    Unraveling PINK1 regulation: Ubiquitination of its mature form and insights for Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27171.
    PubMed     Text format    


  33. MACLEOD AD, Dalen I, Tysnes OB, Larsen JP, et al
    Development and validation of prognostic survival models in newly diagnosed Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27177.
    PubMed     Text format     Abstract available


  34. WEIL RS, Pappa K, Schade RN, Schrag AE, et al
    The Cats-and-Dogs test: A tool to identify visuoperceptual deficits in Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27176.
    PubMed     Text format    


  35. FORD KJ, Joop A, Memon RA, Wood KH, et al
    Pedestrian safety in patients with Parkinson's disease: A case-control study.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27124.
    PubMed     Text format     Abstract available


  36. STANDAERT DG
    What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's disease.
    Mov Disord. 2017;32:1341-1342.
    PubMed     Text format    


    September 2017
  37. THEVATHASAN W, Debu B, Aziz T, Bloem BR, et al
    Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: A clinical review.
    Mov Disord. 2017 Sep 28. doi: 10.1002/mds.27098.
    PubMed     Text format     Abstract available


  38. BIUNDO R, Weis L, Abbruzzese G, Calandra-Buonaura G, et al
    Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study.
    Mov Disord. 2017 Sep 27. doi: 10.1002/mds.27181.
    PubMed     Text format     Abstract available


  39. TESSITORE A, De Micco R, Giordano A, di Nardo F, et al
    Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson's disease.
    Mov Disord. 2017 Sep 26. doi: 10.1002/mds.27139.
    PubMed     Text format     Abstract available


  40. ROSE SJ, Harrast P, Donsante C, Fan X, et al
    Parkinsonism without dopamine neuron degeneration in aged l-dopa-responsive dystonia knockin mice.
    Mov Disord. 2017 Sep 26. doi: 10.1002/mds.27169.
    PubMed     Text format     Abstract available


  41. FULLARD ME, Xie SX, Marek K, Stern M, et al
    Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.
    Mov Disord. 2017 Sep 14. doi: 10.1002/mds.27127.
    PubMed     Text format     Abstract available


  42. SAME K, Ghazi Sherbaf F, Aarabi MH
    New link between Parkinson's and Alzheimer's: Research uncovers the role of mutant leucine rich repeat kinase 2 and amyloid precursor protein.
    Mov Disord. 2017 Sep 13. doi: 10.1002/mds.27170.
    PubMed     Text format    


  43. FRISALDI E, Carlino E, Zibetti M, Barbiani D, et al
    The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning.
    Mov Disord. 2017 Sep 12. doi: 10.1002/mds.27142.
    PubMed     Text format     Abstract available


  44. YANG F, Wolk A, Hakansson N, Pedersen NL, et al
    Dietary antioxidants and risk of Parkinson's disease in two population-based cohorts.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27120.
    PubMed     Text format     Abstract available


  45. HAN W, Sapkota S, Camicioli R, Dixon RA, et al
    Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27173.
    PubMed     Text format     Abstract available


  46. GHAHREMANI A, Chen R
    Deep brain stimulation modulates the shape of cortical beta oscillations in Parkinson's disease.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27144.
    PubMed     Text format    


  47. EUSEBI P, Giannandrea D, Biscetti L, Abraha I, et al
    Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27110.
    PubMed     Text format     Abstract available


  48. BRAKEDAL B, Flones I, Reiter SF, Torkildsen O, et al
    Glitazone use associated with reduced risk of Parkinson's disease.
    Mov Disord. 2017 Sep 1. doi: 10.1002/mds.27128.
    PubMed     Text format     Abstract available


  49. OBESO JA, Stamelou M, Goetz CG, Poewe W, et al
    Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.
    Mov Disord. 2017;32:1264-1310.
    PubMed     Text format     Abstract available



  50. Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative
    Mov Disord. 2017;32:e1-e19.
    PubMed     Text format    


    August 2017
  51. TREZZI JP, Galozzi S, Jaeger C, Barkovits K, et al
    Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27132.
    PubMed     Text format     Abstract available


  52. HEINTZ-BUSCHART A, Pandey U, Wicke T, Sixel-Doring F, et al
    The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27105.
    PubMed     Text format     Abstract available


  53. TURCANO P, Mielke MM, Josephs KA, Bower JH, et al
    Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27125.
    PubMed     Text format     Abstract available


  54. PARNETTI L, Paciotti S, Eusebi P, Dardis A, et al
    Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in parkinson's disease patients.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27136.
    PubMed     Text format     Abstract available


  55. BORGHAMMER P
    How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27138.
    PubMed     Text format     Abstract available


  56. OERTEL W, Eggert K, Pahwa R, Tanner CM, et al
    Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Mov Disord. 2017 Aug 21. doi: 10.1002/mds.27131.
    PubMed     Text format     Abstract available


  57. CHAUDHURI KR, Jenner P
    Two hundred years since James Parkinson's essay on the shaking palsy-Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017.
    Mov Disord. 2017 Aug 11. doi: 10.1002/mds.27104.
    PubMed     Text format    


  58. POLLARD EE
    Where we've gone "right" in the Parkinson's community.
    Mov Disord. 2017 Aug 11. doi: 10.1002/mds.27076.
    PubMed     Text format    


  59. ROCCA WA
    The future burden of Parkinson's disease.
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27114.
    PubMed     Text format    


  60. MIYAUE N, Tada S, Ando R, Yabe H, et al
    cascade stomach associated with delayed-on or no-on phenomenon in a patient with Parkinson's disease.
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27109.
    PubMed     Text format    


  61. BANDRES-CIGA S, Cookson MR
    Alpha-synuclein triggers T-cell response. Is Parkinson's disease an autoimmune disorder?
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27116.
    PubMed     Text format    


  62. GARCIA-SANZ P, Orgaz L, Bueno-Gil G, Espadas I, et al
    N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.
    Mov Disord. 2017 Aug 5. doi: 10.1002/mds.27119.
    PubMed     Text format     Abstract available


  63. LILL CM, Klein C
    What would Dr. James Parkinson think today? The role of genetics in Parkinson's disease.
    Mov Disord. 2017;32:1115-1116.
    PubMed     Text format    


    July 2017
  64. CHUNG SJ, Shin JH, Cho KH, Lee Y, et al
    Subcortical shape analysis of progressive mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2017 Jul 24. doi: 10.1002/mds.27106.
    PubMed     Text format     Abstract available


  65. DELPONT B, Lhommee E, Klinger H, Schmitt E, et al
    Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
    Mov Disord. 2017 Jul 24. doi: 10.1002/mds.27101.
    PubMed     Text format     Abstract available


  66. OFORI E, Krismer F, Burciu RG, Pasternak O, et al
    Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study.
    Mov Disord. 2017 Jul 17. doi: 10.1002/mds.27100.
    PubMed     Text format     Abstract available


  67. THIBAULT L, Rascol O, Corvol JC, Ferreira J, et al
    New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.
    Mov Disord. 2017 Jul 13. doi: 10.1002/mds.27055.
    PubMed     Text format    


  68. PAYAMI H
    The emerging science of precision medicine and pharmacogenomics for Parkinson's disease.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27099.
    PubMed     Text format     Abstract available


  69. KOJOVIC M, Kassavetis P, Parees I, Georgiev D, et al
    Pathophysiological heterogeneity in Parkinson's disease: Neurophysiological insights from LRRK2 mutations.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27091.
    PubMed     Text format    


  70. CORREIA GUEDES L, Reimao S, Paulino P, Nunes RG, et al
    Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27083.
    PubMed     Text format    


  71. HEINZEL S, Bernhard FP, Roeben B, Nussbaum S, et al
    Progression markers of motor deficits in Parkinson's disease: A biannual 4-year prospective study.
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27062.
    PubMed     Text format    


  72. SAEZ-ATIENZAR S, Singleton AB
    Parkinson Disease and Clathrin Coat Dynamics at Synapses, Why Not?
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27097.
    PubMed     Text format    


  73. SONG N, Wang W, Jia F, Du X, et al
    Assessments of plasma ghrelin levels in the early stages of parkinson's disease.
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27095.
    PubMed     Text format     Abstract available


  74. HUANG P, Tan YY, Liu DQ, Herzallah MM, et al
    Motor-symptom laterality affects acquisition in Parkinson's disease: A cognitive and functional magnetic resonance imaging study.
    Mov Disord. 2017;32:1047-1055.
    PubMed     Text format     Abstract available


  75. OBESO JA, Trenkwalder C
    What would Dr. James Parkinson think today? The 21st Annual Congress of the International Parkinson's disease and movement disorders society.
    Mov Disord. 2017;32:951-954.
    PubMed     Text format    


    June 2017
  76. ZABETIAN CP, Mata IF
    LARGE-PD: Examining the genetics of Parkinson's disease in Latin America.
    Mov Disord. 2017 Jun 28. doi: 10.1002/mds.27081.
    PubMed     Text format    


  77. GOETZ CG, Stebbins GT, Chung KA, Nicholas AP, et al
    Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study.
    Mov Disord. 2017 Jun 24. doi: 10.1002/mds.27092.
    PubMed     Text format    


  78. LHOMMEE E, Boyer F, Wack M, Pelissier P, et al
    Personality, dopamine, and Parkinson's disease: Insights from subthalamic stimulation.
    Mov Disord. 2017 Jun 23. doi: 10.1002/mds.27065.
    PubMed     Text format     Abstract available


  79. STEINER LA, Neumann WJ, Staub-Bartelt F, Herz DM, et al
    Subthalamic beta dynamics mirror Parkinsonian bradykinesia months after neurostimulator implantation.
    Mov Disord. 2017 Jun 22. doi: 10.1002/mds.27068.
    PubMed     Text format     Abstract available


  80. CHOTIBUT T, Meadows S, Kasanga EA, McInnis T, et al
    Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27077.
    PubMed     Text format     Abstract available


  81. BONET-PONCE L, Singleton AB
    Make dopamine neurons great again: An exciting new therapeutic option in parkinson's disease.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27078.
    PubMed     Text format    


  82. CLAASSEN DO, Stark AJ, Spears CA, Petersen KJ, et al
    Mesocorticolimbic hemodynamic response in Parkinson's disease patients with compulsive behaviors.
    Mov Disord. 2017 Jun 19. doi: 10.1002/mds.27047.
    PubMed     Text format     Abstract available


  83. PELOSI A
    Cell-specific alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonism reveals new insights in the development of parkinson's disease.
    Mov Disord. 2017 Jun 16. doi: 10.1002/mds.27071.
    PubMed     Text format    


  84. FRIEDMAN JH
    Drug-induced parkinsonism.
    Mov Disord. 2017 Jun 14. doi: 10.1002/mds.27050.
    PubMed     Text format    


  85. ROCCA WA, Savica R, Grossardt BR
    Response to Letter by Friedman on "Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study".
    Mov Disord. 2017 Jun 14. doi: 10.1002/mds.27051.
    PubMed     Text format    


  86. HOOGLAND J, Boel JA, de Bie RMA, Geskus RB, et al
    Mild cognitive impairment as a risk factor for Parkinson's disease dementia.
    Mov Disord. 2017 Jun 12. doi: 10.1002/mds.27002.
    PubMed     Text format     Abstract available


  87. TITOVA N, Chaudhuri KR
    Personalized medicine in Parkinson's disease: Time to be precise.
    Mov Disord. 2017 Jun 12. doi: 10.1002/mds.27027.
    PubMed     Text format    


  88. LARSSON SC, Singleton AB, Nalls MA, Richards JB, et al
    No clear support for a role for vitamin D in Parkinson's disease: A Mendelian randomization study.
    Mov Disord. 2017 Jun 8. doi: 10.1002/mds.27069.
    PubMed     Text format     Abstract available


  89. ROSSI A, Berger K, Chen H, Leslie D, et al
    Projection of the prevalence of Parkinson's disease in the coming decades: Revisited.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27063.
    PubMed     Text format     Abstract available


  90. KASSUBEK J, Huppertz HJ, Hoglinger GU
    Reply to: MRI measures of brainstem in parkinsonian syndromes: Where we stand and where we need to go.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27057.
    PubMed     Text format    


  91. KUMAR A
    Reprogramming the striatal stars: A new treatment option for Parkinson's disease.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27067.
    PubMed     Text format    


  92. QUATTRONE A, Nigro S
    MRI measures of brainstem in Parkinsonian syndromes: Where we stand and where we need to go.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27056.
    PubMed     Text format    


  93. MAHLKNECHT P, Akram H, Georgiev D, Tripoliti E, et al
    Pyramidal tract activation due to subthalamic deep brain stimulation in Parkinson's disease.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27042.
    PubMed     Text format     Abstract available


  94. PINA-FUENTES D, Little S, Oterdoom M, Neal S, et al
    Adaptive DBS in a Parkinson's patient with chronically implanted DBS: A proof of principle.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.26959.
    PubMed     Text format    



  95. Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2017;32 Suppl 2:S1-S1079.
    PubMed     Text format    


  96. MANDEMAKERS W, Quadri M, Stamelou M, Bonifati V, et al
    TMEM230: How does it fit in the etiology and pathogenesis of Parkinson's disease?
    Mov Disord. 2017 Jun 1. doi: 10.1002/mds.27061.
    PubMed     Text format     Abstract available


  97. PEREZ-SORIANO A, Arena JE, Dinelle K, Miao Q, et al
    PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins.
    Mov Disord. 2017 Jun 1. doi: 10.1002/mds.27029.
    PubMed     Text format     Abstract available


  98. AKRAM H, Wu C, Hyam J, Foltynie T, et al
    l-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease.
    Mov Disord. 2017;32:874-883.
    PubMed     Text format     Abstract available


  99. VAILLANCOURT DE
    What Would Dr. James Parkinson Think Today? Tau and Other Imaging Possibilities in Parkinson's Disease.
    Mov Disord. 2017;32:805-806.
    PubMed     Text format    


  100. LENKA A, Pal PK
    "Miro" in Parkinson's disease: Here, there, everywhere!
    Mov Disord. 2017;32:839.
    PubMed     Text format    


    May 2017
  101. NG ASL, Tan EK
    Linking statins and lipids in Parkinson's disease.
    Mov Disord. 2017 May 27. doi: 10.1002/mds.27053.
    PubMed     Text format    


  102. DELGADO-ALVARADO M, Gago B, Gorostidi A, Jimenez-Urbieta H, et al
    Tau/alpha-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Mov Disord. 2017 May 26. doi: 10.1002/mds.27001.
    PubMed     Text format     Abstract available


  103. KIM YJ, Jeon J, Shin J, Kim NY, et al
    Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease.
    Mov Disord. 2017 May 26. doi: 10.1002/mds.27019.
    PubMed     Text format     Abstract available


  104. COLLIER TJ, Kanaan NM, Kordower JH
    Aging and Parkinson's disease: Different sides of the same coin?
    Mov Disord. 2017 May 18. doi: 10.1002/mds.27037.
    PubMed     Text format     Abstract available


  105. PILOTTO A, Heinzel S, Suenkel U, Lerche S, et al
    Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts.
    Mov Disord. 2017 May 16. doi: 10.1002/mds.27035.
    PubMed     Text format     Abstract available


  106. SHAHMOON S, Jahanshahi M
    Optimizing psychosocial adjustment after deep brain stimulation of the subthalamic nucleus in Parkinson's disease.
    Mov Disord. 2017 May 15. doi: 10.1002/mds.27032.
    PubMed     Text format    


  107. YADAV AP, Nicolelis MAL
    Electrical stimulation of the dorsal columns of the spinal cord for Parkinson's disease.
    Mov Disord. 2017 May 12. doi: 10.1002/mds.27033.
    PubMed     Text format     Abstract available


  108. MEROLA A, Rosso M, Romagnolo A, Comi C, et al
    Peripheral neuropathy as marker of severe Parkinson's disease phenotype.
    Mov Disord. 2017 May 8. doi: 10.1002/mds.27025.
    PubMed     Text format    


  109. MARRAS C, Lang A, van de Warrenburg BP, Sue CM, et al
    Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force.
    Mov Disord. 2017;32:724-725.
    PubMed     Text format    


  110. POSTUMA RB
    Sleep Disorders and RBD: What Would James Parkinson Think?
    Mov Disord. 2017;32:705-707.
    PubMed     Text format    


  111. ST LOUIS EK, Boeve AR, Boeve BF
    REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies.
    Mov Disord. 2017;32:645-658.
    PubMed     Text format     Abstract available


  112. ADLER CH, Dugger BN, Hentz JG, Hinni ML, et al
    Peripheral synucleinopathy in early Parkinson's disease: Submandibular gland needle biopsy findings.
    Mov Disord. 2017;32:722-723.
    PubMed     Text format    


    April 2017
  113. STROUWEN C, Molenaar EALM, Munks L, Keus SHJ, et al
    Training dual tasks together or apart in Parkinson's disease: Results from the DUALITY trial.
    Mov Disord. 2017 Apr 25. doi: 10.1002/mds.27014.
    PubMed     Text format     Abstract available


  114. DIEZ H, Cortes-Saladelafont E, Ormazabal A, Marmiese AF, et al
    Severe infantile parkinsonism because of a de novo mutation on DLP1 mitochondrial-peroxisomal protein.
    Mov Disord. 2017 Apr 24. doi: 10.1002/mds.27021.
    PubMed     Text format    


  115. OLSZEWSKA DA, Lynch T
    Nature's Parkin experiment: Nix-a novel protective mechanism in Parkinson's disease.
    Mov Disord. 2017 Apr 22. doi: 10.1002/mds.27015.
    PubMed     Text format    


  116. BEAULIEU ML, Muller MLTM, Bohnen NI
    Have we been overestimating fall rates in Parkinson's disease?
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.26994.
    PubMed     Text format    


  117. LORD S, Galna B, Yarnall AJ, Coleman S, et al
    Have we been overestimating fall rates in Parkinson's disease?
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.27009.
    PubMed     Text format    


  118. FERESHTEHNEJAD SM, Montplaisir JY, Pelletier A, Gagnon JF, et al
    Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort.
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.26989.
    PubMed     Text format     Abstract available


  119. BURTE F, Houghton D, Lowes H, Pyle A, et al
    metabolic profiling of Parkinson's disease and mild cognitive impairment.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.26992.
    PubMed     Text format     Abstract available


  120. KOOLE M, Laere KV, Ahmad R, Ceccarini J, et al
    Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.27005.
    PubMed     Text format    


  121. CACACE F, Mineo D, Viscomi MT, Latagliata EC, et al
    Intermittent theta-burst stimulation rescues dopamine-dependent corticostriatal synaptic plasticity and motor behavior in experimental parkinsonism: Possible role of glial activity.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.26982.
    PubMed     Text format     Abstract available


  122. YANG X, An R, Xi J, Zheng J, et al
    Sequencing TMEM230 in Chinese patients with sporadic or familial Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26996.
    PubMed     Text format    


  123. OLANOW CW, Kieburtz K, Leinonen M, Elmer L, et al
    A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26941.
    PubMed     Text format     Abstract available


  124. LIU G, Sterling NW, Kong L, Lewis MM, et al
    Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.27006.
    PubMed     Text format     Abstract available


  125. KORDOWER JH
    What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias.
    Mov Disord. 2017;32:483-484.
    PubMed     Text format    


  126. BALCK A, Klein C
    Reduced penetrance of Leucine-rich repeat kinase 2 mutations: Discovering genetic factors of endogenous disease protection.
    Mov Disord. 2017;32:527.
    PubMed     Text format    


    March 2017
  127. ORGAZ L, Gil GB
    Modulating mitochondrial pyruvate carrier: A promising therapeutic target in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26962.
    PubMed     Text format    


  128. FOX SH, Metman LV, Nutt JG, Brodsky M, et al
    Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26976.
    PubMed     Text format     Abstract available


  129. PONT-SUNYER C, Tolosa E, Caspell-Garcia C, Coffey C, et al
    The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26964.
    PubMed     Text format     Abstract available


  130. LEHERICY S, Vaillancourt DE, Seppi K, Monchi O, et al
    The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26968.
    PubMed     Text format     Abstract available


  131. BARICHELLA M, Cereda E, Cassani E, Frazzitta G, et al
    A focus on Rome III criteria for the assessment of constipation in Parkinson's disease.
    Mov Disord. 2017 Mar 25. doi: 10.1002/mds.26974.
    PubMed     Text format    


  132. XU T, Wang S, Lalchandani RR, Ding JB, et al
    Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex.
    Mov Disord. 2017 Mar 25. doi: 10.1002/mds.26938.
    PubMed     Text format     Abstract available


  133. MEROLA A, Romagnolo A, Comi C, Rosso M, et al
    Prevalence and burden of dysautonomia in advanced Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26970.
    PubMed     Text format    


  134. F HERNANDEZ L, Castela I, Ruiz-DeDiego I, Obeso JA, et al
    Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26947.
    PubMed     Text format     Abstract available


  135. ANDERKOVA L, Barton M, Rektorova I
    Striato-cortical connections in Parkinson's and Alzheimer's diseases: Relation to cognition.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26956.
    PubMed     Text format     Abstract available


  136. PAGANO G, Niccolini F, Yousaf T, Wilson H, et al
    Urinary dysfunction in early de novo patients with Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26967.
    PubMed     Text format    


  137. PEREZ XA, Zhang D, Bordia T, Quik M, et al
    Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26955.
    PubMed     Text format     Abstract available


  138. HANSEN AK, Damholdt MF, Fedorova TD, Knudsen K, et al
    In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26961.
    PubMed     Text format     Abstract available


  139. GIANNOCCARO MP, La Morgia C, Rizzo G, Carelli V, et al
    Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease.
    Mov Disord. 2017 Mar 2. doi: 10.1002/mds.26966.
    PubMed     Text format     Abstract available


  140. MARRAS C
    What Would Dr. James Parkinson Think Today III: Measuring Health-Related Quality of Life.
    Mov Disord. 2017;32:364-365.
    PubMed     Text format    


    February 2017
  141. ESPAY AJ, Schwarzschild MA, Tanner CM, Fernandez HH, et al
    Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
    Mov Disord. 2017 Feb 24. doi: 10.1002/mds.26913.
    PubMed     Text format     Abstract available


  142. HORVATH K, Aschermann Z, Kovacs M, Makkos A, et al
    Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale.
    Mov Disord. 2017 Feb 20. doi: 10.1002/mds.26960.
    PubMed     Text format     Abstract available


  143. MIKI Y, Yoshizawa T, Morohashi S, Seino Y, et al
    Neuropathology of PARK14 is identical to idiopathic Parkinson's disease.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26952.
    PubMed     Text format    


  144. ROSA M, Arlotti M, Marceglia S, Cogiamanian F, et al
    Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26953.
    PubMed     Text format    


  145. HILL-BURNS EM, Debelius JW, Morton JT, Wissemann WT, et al
    Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
    Mov Disord. 2017 Feb 14. doi: 10.1002/mds.26942.
    PubMed     Text format     Abstract available


  146. PONZO V, Di Lorenzo F, Brusa L, Schirinzi T, et al
    Impaired intracortical transmission in G2019S leucine rich-repeat kinase Parkinson patients.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26931.
    PubMed     Text format     Abstract available


  147. ANSARI M, Sobhani S
    Impaired glutamate release in GPe astrocytes, disinhibits striatopallidal transmission in Parkinsonian mice.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26943.
    PubMed     Text format    


  148. GALLEA C, Ewenczyk C, Degos B, Welter ML, et al
    Pedunculopontine network dysfunction in Parkinson's disease with postural control and sleep disorders.
    Mov Disord. 2017 Feb 6. doi: 10.1002/mds.26923.
    PubMed     Text format     Abstract available


  149. DEL REY NL, Blesa J
    Parkinson's disease: Oh my gut!
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26933.
    PubMed     Text format    


  150. MAHLKNECHT P, Krismer F, Poewe W, Seppi K, et al
    Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26932.
    PubMed     Text format     Abstract available


  151. MOLLER L, Kassubek J, Sudmeyer M, Hilker R, et al
    Manual MRI morphometry in Parkinsonian syndromes.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26921.
    PubMed     Text format     Abstract available


  152. STRAFELLA AP, Bohnen NI, Perlmutter JS, Eidelberg D, et al
    Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26907.
    PubMed     Text format     Abstract available


  153. OLANOW CW, Kordower JH
    Targeting alpha-Synuclein as a therapy for Parkinson's disease: The battle begins.
    Mov Disord. 2017;32:203-207.
    PubMed     Text format    


  154. ALBIN RL
    What would Dr. James Parkinson think today? II. Neuroimaging in Parkinson's disease.
    Mov Disord. 2017;32:179-180.
    PubMed     Text format    


  155. EBRAHIMI R, Sobhani S, Abbastabar M
    Whether the dissociation between toxicity and alpha-synuclein inclusion will be a possible therapy for Parkinson's disease or not?
    Mov Disord. 2017;32:210.
    PubMed     Text format    



  156. Abstracts of the 1st Pan American Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2017;32 Suppl 1:S1-S90.
    PubMed     Text format    


    January 2017
  157. MORBERG BM, Malling AS, Jensen BR, Gredal O, et al
    Parkinson's disease and transcranial pulsed electromagnetic fields: A randomized clinical trial.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26927.
    PubMed     Text format    


  158. VIDENOVIC A
    Management of sleep disorders in Parkinson's disease and multiple system atrophy.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26918.
    PubMed     Text format     Abstract available


  159. NOYCE AJ, R'Bibo L, Peress L, Bestwick JP, et al
    PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26898.
    PubMed     Text format     Abstract available


  160. QUADRI M, Breedveld GJ, Chang HC, Yeh TH, et al
    Mutations in TMEM230 are not a common cause of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26900.
    PubMed     Text format    


  161. MOHASEL S, Sobhani S
    The role of amyloidogenic proteins as a meeting point of type 2 diabetes and Parkinson's disease pathways.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26897.
    PubMed     Text format    


  162. VISANJI NP, Bhudhikanok GS, Mestre TA, Ghate T, et al
    Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26896.
    PubMed     Text format     Abstract available


  163. SCHNEIDER SA, Bras J
    Mouse models of kufor-rakeb disease link Parkinson's disease closer to neuronal ceroid lipofuscinosis, suggesting lysosomal dysfunction as shared mechanism.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26899.
    PubMed     Text format    


  164. BESTE C, Muckschel M, Rosales R, Domingo A, et al
    Striosomal dysfunction affects behavioral adaptation but not impulsivity-Evidence from X-linked dystonia-parkinsonism.
    Mov Disord. 2017 Jan 6. doi: 10.1002/mds.26895.
    PubMed     Text format     Abstract available


  165. SPATARO N, Roca-Umbert A, Cervera-Carles L, Valles M, et al
    Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients.
    Mov Disord. 2017;32:165-169.
    PubMed     Text format     Abstract available


  166. ZHANG M, Xi Z, Misquitta K, Sato C, et al
    C9orf72 and ATXN2 repeat expansions coexist in a family with ataxia, dementia, and parkinsonism.
    Mov Disord. 2017;32:158-162.
    PubMed     Text format     Abstract available


  167. HARIZ M, Obeso JA
    What Would Dr. James Parkinson Think Today? I. The Role of Functional Neurosurgery for Parkinson's Disease.
    Mov Disord. 2017;32:2-4.
    PubMed     Text format    


    December 2016
  168. LANGLEY J, Huddleston DE, Sedlacik J, Boelmans K, et al
    Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26883.
    PubMed     Text format     Abstract available


  169. RAHMANI F, Kamalian A, Aarabi MH
    New evidence comes to light: How is alpha-synuclein aggregation related to mitochondrial protein import in Parkinson's disease?
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26889.
    PubMed     Text format    


  170. BLAUWENDRAAT C, Nalls MA, Federoff M, Pletnikova O, et al
    ADORA1 mutations are not a common cause of Parkinson's disease and dementia with Lewy bodies.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26886.
    PubMed     Text format    


  171. SENEK M, Nielsen EI, Nyholm D
    Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26855.
    PubMed     Text format     Abstract available


  172. PAL GD, Ouyang B, Serrano G, Shill HA, et al
    Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26882.
    PubMed     Text format     Abstract available


  173. DZAMKO N, Gysbers AM, Bandopadhyay R, Bolliger MF, et al
    LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26892.
    PubMed     Text format     Abstract available


  174. MARTINEZ-MARTIN P
    What is quality of life and how do we measure it? Relevance to Parkinson's disease and movement disorders.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26885.
    PubMed     Text format     Abstract available


  175. GOETZ CG, Liu Y, Stebbins GT, Wang L, et al
    Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale.
    Mov Disord. 2016;31:1865-1873.
    PubMed     Text format     Abstract available


  176. WILLIS AW, Thibault DP, Schmidt PN, Dorsey ER, et al
    Hospital care for mental health and substance abuse conditions in Parkinson's disease.
    Mov Disord. 2016;31:1810-1819.
    PubMed     Text format     Abstract available


  177. SHI CH, Zhang SY, Yang ZH, Yang J, et al
    A novel RAB39B gene mutation in X-linked juvenile parkinsonism with basal ganglia calcification.
    Mov Disord. 2016;31:1905-1909.
    PubMed     Text format     Abstract available


    November 2016
  178. DE PABLO-FERNANDEZ E, Courtney R, Holton JL, Warner TT, et al
    Hypothalamic alpha-synuclein and its relation to weight loss and autonomic symptoms in Parkinson's disease.
    Mov Disord. 2016 Nov 28. doi: 10.1002/mds.26868.
    PubMed     Text format    


  179. KNUDSEN K, Krogh K, Ostergaard K, Borghammer P, et al
    Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26866.
    PubMed     Text format     Abstract available


  180. PILLAS M, Selai C, Schrag A
    Rasch analysis of the carers quality of life questionnaire for parkinsonism.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26877.
    PubMed     Text format     Abstract available


  181. RAUSCHENDORF MA, Jost M, Stock F, Zimmer A, et al
    Novel compound heterozygous synaptojanin-1 mutation causes l-dopa-responsive dystonia-parkinsonism syndrome.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26876.
    PubMed     Text format    


  182. HE YC, Huang P, Li QQ, Sun Q, et al
    TMEM230 stop codon mutation is rare in parkinson's disease and essential tremor in eastern China.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26875.
    PubMed     Text format    


  183. POLITIS M, Sauerbier A, Loane C, Pavese N, et al
    Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.
    Mov Disord. 2016 Nov 17. doi: 10.1002/mds.26848.
    PubMed     Text format     Abstract available


  184. GALIMBERTI D, Cioffi SM, Fenoglio C, Serpente M, et al
    Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26872.
    PubMed     Text format    


  185. FIFEL K
    Alterations of the circadian system in Parkinson's disease patients.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26865.
    PubMed     Text format     Abstract available


  186. ISOTALO J, Vahlberg T, Kaasinen V
    Unchanged long-term rural-to-urban incidence ratio of Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26862.
    PubMed     Text format    


  187. XIE T, Kang UJ
    Comments on the recent viewpoint article on low-frequency deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26861.
    PubMed     Text format    


  188. GAARE JJ, Skeie GO, Tzoulis C, Larsen JP, et al
    Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26856.
    PubMed     Text format     Abstract available


  189. PINTO DE SOUZA C, Hamani C, Oliveira Souza C, Lopez Contreras WO, et al
    Spinal cord stimulation improves gait in patients with Parkinson's disease previously treated with deep brain stimulation.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26850.
    PubMed     Text format     Abstract available


  190. KLETTNER A, Tholey A, Wiegandt A, Richert E, et al
    Reduction of GAPDH in lenses of Parkinson's disease patients: A possible new biomarker.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26863.
    PubMed     Text format     Abstract available


  191. BEUDEL M, Oswal A, Jha A, Foltynie T, et al
    Oscillatory Beta Power Correlates With Akinesia-Rigidity in the Parkinsonian Subthalamic Nucleus.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26860.
    PubMed     Text format    


  192. DI BIASE L, Fasano A
    Reply to: Comments on recent viewpoint article by Lazzaro di Biase and Alfonso Fasano titled "Low-frequency deep brain stimulation for Parkinson's disease: Great expectation or false hope?"
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26859.
    PubMed     Text format    


  193. NEUMANN WJ, Kuhn AA
    Subthalamic beta power-Unified Parkinson's disease rating scale III correlations require akinetic symptoms.
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26858.
    PubMed     Text format    


  194. SGAMBATO-FAURE V
    Control of the direct pathway by cholinergic interneurons is involved in parkinsonian motor symptoms.
    Mov Disord. 2016 Nov 2. doi: 10.1002/mds.26840.
    PubMed     Text format    


    October 2016
  195. FOO JN, Lee J, Tan LC, Liu J, et al
    Large 3-Mb deletions at 22q11.2 locus in parkinson's disease and schizophrenia.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26822.
    PubMed     Text format    


  196. HUGHES KC, Gao X, Kim IY, Rimm EB, et al
    Intake of antioxidant vitamins and risk of parkinson's disease.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26819.
    PubMed     Text format     Abstract available


  197. TINAZZI M, Geroin C, Gandolfi M, Smania N, et al
    Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26829.
    PubMed     Text format     Abstract available


  198. MANGESIUS S, Krismer F, Gizewski ER, Muller C, et al
    1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26823.
    PubMed     Text format    


  199. SAVICA R, Grossardt BR, Bower JH, Ahlskog JE, et al
    Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26839.
    PubMed     Text format     Abstract available


  200. TARSY D
    Addition of a virtual reality component to treadmill training to reduce fall risk in older adults, including individuals with Parkinson's disease.
    Mov Disord. 2016 Oct 19. doi: 10.1002/mds.26843.
    PubMed     Text format    


  201. KHODADADI H, Azcona LJ, Aghamollaii V, Omrani MD, et al
    PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26824.
    PubMed     Text format     Abstract available


  202. TROSTER AI, Jankovic J, Tagliati M, Peichel D, et al
    Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26827.
    PubMed     Text format     Abstract available


  203. PYLE A, Lowes H, Brennan R, Kurzawa-Akanbi M, et al
    Reduced mitochondrial DNA is not a biomarker of depression in Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26825.
    PubMed     Text format    


  204. BALINT B, Bhatia KP
    SLC39A14 mutations expand the spectrum of manganese transporter defects causing parkinsonism-dystonia.
    Mov Disord. 2016 Oct 14. doi: 10.1002/mds.26821.
    PubMed     Text format    


  205. KLEIN C, Lochte T, Delamonte SM, Braenne I, et al
    PLA2G6 mutations and Parkinsonism: Long-term follow-up of clinical Features and Neuropathology.
    Mov Disord. 2016 Oct 6. doi: 10.1002/mds.26814.
    PubMed     Text format    


  206. POLLI A, Weis L, Biundo R, Thacker M, et al
    Anatomical and functional correlates of persistent pain in parkinson's disease.
    Mov Disord. 2016 Oct 5. doi: 10.1002/mds.26826.
    PubMed     Text format     Abstract available


    September 2016
  207. PONS R, Kekou K, Antonellou R, Svingou M, et al
    Analysis of a founder mutation in the TH gene in a cohort of greek patients with Parkinson's disease.
    Mov Disord. 2016 Sep 26. doi: 10.1002/mds.26807.
    PubMed     Text format    


  208. SVENSSON E, Horvath-Puho E, Stokholm MG, Sorensen HT, et al
    Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26761.
    PubMed     Text format     Abstract available


  209. LORD S, Galna B, Yarnall AJ, Coleman S, et al
    Predicting first fall in newly diagnosed Parkinson's disease: Insights from a fall-naive cohort.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26742.
    PubMed     Text format     Abstract available


  210. WONG YC, Krainc D
    Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26802.
    PubMed     Text format     Abstract available


  211. KETT LR, Dauer WT
    Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26797.
    PubMed     Text format     Abstract available


  212. RIEDEL O
    Bringing light into the darkness: Dependence in Parkinson's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26795.
    PubMed     Text format    


  213. DELVAL A, Rambour M, Tard C, Dujardin K, et al
    Freezing/festination during motor tasks in early-stage Parkinson's disease: A prospective study.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26762.
    PubMed     Text format     Abstract available


    August 2016
  214. KIM JM, Jang ES, Ok K, Oh ES, et al
    Association between hepatitis C virus infection and Parkinson's disease.
    Mov Disord. 2016 Aug 23. doi: 10.1002/mds.26755.
    PubMed     Text format    


  215. MAJBOUR NK, Vaikath NN, Eusebi P, Chiasserini D, et al
    Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26754.
    PubMed     Text format     Abstract available


  216. ONDER H
    Dominant-side onset in Parkinson's disease and better motor performance?
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26752.
    PubMed     Text format    


  217. MACLEOD AD, Counsell CE
    Predictors of functional dependency in Parkinson's disease.
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26751.
    PubMed     Text format     Abstract available


  218. SOHN YH, Ham JH
    Dominant-side onset in Parkinson's disease and better motor performance?
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26750.
    PubMed     Text format    


  219. NEUMANN WJ, Degen K, Schneider GH, Brucke C, et al
    Subthalamic synchronized oscillatory activity correlates with motor impairment in patients with Parkinson's disease.
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26759.
    PubMed     Text format     Abstract available


  220. FIGGE DA, Standaert DG
    SNPing SCNA regulatory elements gives a CRISPR view of genetic susceptibility in Parkinson's disease.
    Mov Disord. 2016 Aug 8. doi: 10.1002/mds.26747.
    PubMed     Text format    


  221. DORSEY ER, Vlaanderen FP, Engelen LJ, Kieburtz K, et al
    Moving Parkinson care to the home.
    Mov Disord. 2016 Aug 8. doi: 10.1002/mds.26744.
    PubMed     Text format     Abstract available


  222. VARANDA S, Ribeiro da Silva J, Costa AS, Amorim de Carvalho C, et al
    Sexual dysfunction in women with Parkinson's disease.
    Mov Disord. 2016 Aug 8. doi: 10.1002/mds.26739.
    PubMed     Text format     Abstract available


  223. KUBOTA KJ, Chen JA, Little MA
    Machine learning for large-scale wearable sensor data in Parkinson's disease: Concepts, promises, pitfalls, and futures.
    Mov Disord. 2016 Aug 8. doi: 10.1002/mds.26693.
    PubMed     Text format     Abstract available


  224. SANCHEZ-FERRO A, Maetzler W
    Advances in sensor and wearable technologies for Parkinson's disease.
    Mov Disord. 2016 Aug 1. doi: 10.1002/mds.26746.
    PubMed     Text format    


  225. PIFL C
    Problems with traffic ahead: Synaptic vesicles in Parkinson's disease.
    Mov Disord. 2016 Aug 1. doi: 10.1002/mds.26735.
    PubMed     Text format    


  226. LAHUE SC, Comella CL, Tanner CM
    The best medicine? The influence of physical activity and inactivity on Parkinson's disease.
    Mov Disord. 2016 Aug 1. doi: 10.1002/mds.26728.
    PubMed     Text format     Abstract available


  227. DAMS J, Balzer-Geldsetzer M, Siebert U, Deuschl G, et al
    Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications.
    Mov Disord. 2016;31:1183-91.
    PubMed     Text format     Abstract available


    July 2016
  228. KRISMER F, Seppi K, Wenning GK, Abler V, et al
    Minimally clinically important decline in the parkinsonian variant of multiple system atrophy.
    Mov Disord. 2016 Jul 30. doi: 10.1002/mds.26743.
    PubMed     Text format     Abstract available


  229. WESSEL JR, Ghahremani A, Udupa K, Saha U, et al
    Stop-related subthalamic beta activity indexes global motor suppression in Parkinson's disease.
    Mov Disord. 2016 Jul 30. doi: 10.1002/mds.26732.
    PubMed     Text format     Abstract available


  230. BERMAN BD, Smucny J, Wylie KP, Shelton E, et al
    Levodopa modulates small-world architecture of functional brain networks in Parkinson's disease.
    Mov Disord. 2016 Jul 27. doi: 10.1002/mds.26713.
    PubMed     Text format     Abstract available


  231. DEL DIN S, Godfrey A, Mazza C, Lord S, et al
    Free-living monitoring of Parkinson's disease: Lessons from the field.
    Mov Disord. 2016 Jul 25. doi: 10.1002/mds.26718.
    PubMed     Text format     Abstract available


  232. HUPPERTZ HJ, Moller L, Sudmeyer M, Hilker R, et al
    Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification.
    Mov Disord. 2016 Jul 25. doi: 10.1002/mds.26715.
    PubMed     Text format     Abstract available


  233. SVENNINGSSON P, Wirdefeldt K, Yin L, Fang F, et al
    Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26734.
    PubMed     Text format    


  234. MARTINEZ-FERNANDEZ R, Schmitt E, Martinez-Martin P, Krack P, et al
    The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26731.
    PubMed     Text format     Abstract available


  235. RASCOL O, Hauser RA, Stocchi F, Fitzer-Attas CJ, et al
    Long-term effects of rasagiline and the natural history of treated Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26724.
    PubMed     Text format     Abstract available


  236. SANCHEZ-FERRO A, Elshehabi M, Godinho C, Salkovic D, et al
    New methods for the assessment of Parkinson's disease (2005 to 2015): A systematic review.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26723.
    PubMed     Text format     Abstract available


  237. MIRELMAN A, Bernad-Elazari H, Thaler A, Giladi-Yacobi E, et al
    Arm swing as a potential new prodromal marker of Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26720.
    PubMed     Text format     Abstract available


  238. NONNEKES J, Timmer MH, de Vries NM, Rascol O, et al
    Unmasking levodopa resistance in Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26712.
    PubMed     Text format     Abstract available


  239. SANKAR T, Li SX, Obuchi T, Fasano A, et al
    Structural brain changes following subthalamic nucleus deep brain stimulation in Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26707.
    PubMed     Text format    


  240. HAUSER RA, Olanow CW, Dzyngel B, Bilbault T, et al
    Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26697.
    PubMed     Text format     Abstract available


  241. LOEFFLER DA, LeWitt PA, Camp DM
    Nocardia asteroides-Induced movement abnormalities in mice: Relevance for Parkinson's disease?
    Mov Disord. 2016 Jul 14. doi: 10.1002/mds.26711.
    PubMed     Text format    


  242. MESTRE TA, Sidiropoulos C, Hamani C, Poon YY, et al
    Long-term double-blinded unilateral pedunculopontine area stimulation in Parkinson's disease.
    Mov Disord. 2016 Jul 9. doi: 10.1002/mds.26710.
    PubMed     Text format     Abstract available



  243. Retraction: 'Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial,' by Sato, Y., Iwamoto, J., Kanoko, T., and Satoh, K.
    Mov Disord. 2016;31:1077.
    PubMed     Text format     Abstract available


    June 2016
  244. ANTUNES L, Frasquilho S, Ostaszewski M, Weber J, et al
    Similar alpha-Synuclein staining in the colon mucosa in patients with Parkinson's disease and controls.
    Mov Disord. 2016 Jun 21. doi: 10.1002/mds.26702.
    PubMed     Text format     Abstract available


  245. DAMS J, Dodel R
    An economic evaluation of deep brain stimulation for patients with Parkinson's disease.
    Mov Disord. 2016 Jun 21. doi: 10.1002/mds.26701.
    PubMed     Text format    


  246. MALEK N, Lawton MA, Swallow DM, Grosset KA, et al
    Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease.
    Mov Disord. 2016 Jun 21. doi: 10.1002/mds.26698.
    PubMed     Text format     Abstract available


  247. FRASER KB, Rawlins AB, Clark RG, Alcalay RN, et al
    Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease.
    Mov Disord. 2016 Jun 14. doi: 10.1002/mds.26686.
    PubMed     Text format     Abstract available


  248. ROSSI M, Escobar AM, Bril A, Millar Vernetti P, et al
    Motor features in Parkinson's disease with normal olfactory function.
    Mov Disord. 2016 Jun 9. doi: 10.1002/mds.26687.
    PubMed     Text format     Abstract available


  249. MAETZLER W, Klucken J, Horne M
    A clinical view on the development of technology-based tools in managing Parkinson's disease.
    Mov Disord. 2016 Jun 7. doi: 10.1002/mds.26673.
    PubMed     Text format     Abstract available


  250. MAHLKNECHT P, Gasperi A, Willeit P, Kiechl S, et al
    Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community.
    Mov Disord. 2016 Jun 6. doi: 10.1002/mds.26674.
    PubMed     Text format     Abstract available


  251. COTELLI M, Manenti R, Brambilla M, Borroni B, et al
    Reply to letter to the editor "tDCS effect on cognitive performance in Parkinson's disease" by Biundo et al.
    Mov Disord. 2016 Jun 6. doi: 10.1002/mds.26684.
    PubMed     Text format    


  252. NAKAMURA T, Suzuki M, Okada A, Suzuki J, et al
    Association of leptin with orthostatic blood pressure changes in Parkinson's disease.
    Mov Disord. 2016 Jun 6. doi: 10.1002/mds.26678.
    PubMed     Text format     Abstract available


  253. BIUNDO R, Weis L, Antonini A
    tDCS effect on cognitive performance in Parkinson's disease.
    Mov Disord. 2016 Jun 2. doi: 10.1002/mds.26685.
    PubMed     Text format    


  254. CALABRESI P, Standaert DG, Chiasserini D, Parnetti L, et al
    Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis.
    Mov Disord. 2016;31:769-70.
    PubMed     Text format    



  255. Abstracts of the Twentieth International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2016;31 Suppl 2:S1-S802.
    PubMed     Text format    


    May 2016
  256. VAN UEM JM, Maier KS, Hucker S, Scheck O, et al
    Twelve-week sensor assessment in Parkinson's disease: Impact on quality of life.
    Mov Disord. 2016 May 31. doi: 10.1002/mds.26676.
    PubMed     Text format    


  257. MARRAS C, Lang AE, Austin PC, Lau C, et al
    Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study.
    Mov Disord. 2016 May 31. doi: 10.1002/mds.26670.
    PubMed     Text format     Abstract available


  258. NUTT JG
    Motor subtype in Parkinson's disease: Different disorders or different stages of disease?
    Mov Disord. 2016 May 26. doi: 10.1002/mds.26657.
    PubMed     Text format    


  259. VENUTO CS, Potter NB, Ray Dorsey E, Kieburtz K, et al
    A review of disease progression models of Parkinson's disease and applications in clinical trials.
    Mov Disord. 2016 May 26. doi: 10.1002/mds.26644.
    PubMed     Text format     Abstract available


  260. HIRSCHMANN J, Butz M, Hartmann CJ, Hoogenboom N, et al
    Parkinsonian Rest Tremor Is Associated With Modulations of Subthalamic High-Frequency Oscillations.
    Mov Disord. 2016 May 23. doi: 10.1002/mds.26663.
    PubMed     Text format     Abstract available


  261. TISON F, Keywood C, Wakefield M, Durif F, et al
    A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
    Mov Disord. 2016 May 23. doi: 10.1002/mds.26659.
    PubMed     Text format     Abstract available


  262. TRENKWALDER C, Stocchi F, Poewe W, Dronamraju N, et al
    Mavoglurant in Parkinson's Patients With l-Dopa-Induced Dyskinesias: Two Randomized Phase 2 Studies.
    Mov Disord. 2016 May 23. doi: 10.1002/mds.26585.
    PubMed     Text format     Abstract available


  263. SCHREGLMANN SR, Houlden H
    VPS13C-Another Hint at Mitochondrial Dysfunction in Familial Parkinson's Disease.
    Mov Disord. 2016 May 23. doi: 10.1002/mds.26682.
    PubMed     Text format    


  264. DELGADO-ALVARADO M, Gago B, Navalpotro-Gomez I, Jimenez-Urbieta H, et al
    Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2016 May 19. doi: 10.1002/mds.26662.
    PubMed     Text format     Abstract available


  265. SHULMAN LM, Armstrong M, Ellis T, Gruber-Baldini A, et al
    Disability Rating Scales in Parkinson's Disease: Critique and Recommendations.
    Mov Disord. 2016 May 19. doi: 10.1002/mds.26649.
    PubMed     Text format     Abstract available


  266. SCHIRINZI T, Madeo G, Martella G, Maltese M, et al
    Early synaptic dysfunction in Parkinson's disease: Insights from animal models.
    Mov Disord. 2016 May 19. doi: 10.1002/mds.26620.
    PubMed     Text format     Abstract available


  267. DI BIASE L, Fasano A
    Low-frequency deep brain stimulation for Parkinson's disease: Great expectation or false hope?
    Mov Disord. 2016 May 13. doi: 10.1002/mds.26658.
    PubMed     Text format     Abstract available


  268. MAHLKNECHT P, Pechlaner R, Boesveldt S, Volc D, et al
    Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease.
    Mov Disord. 2016 May 9. doi: 10.1002/mds.26637.
    PubMed     Text format     Abstract available


  269. BLENNOW K, Biscetti L, Eusebi P, Parnetti L, et al
    Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.
    Mov Disord. 2016 May 4. doi: 10.1002/mds.26656.
    PubMed     Text format     Abstract available


  270. TESSITORE A, Giordano A, De Micco R, Caiazzo G, et al
    Functional connectivity underpinnings of fatigue in "Drug-Naive" patients with Parkinson's disease.
    Mov Disord. 2016 May 4. doi: 10.1002/mds.26650.
    PubMed     Text format     Abstract available


  271. HALBGEBAUER S, Ockl P, Wirth K, Steinacker P, et al
    Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins.
    Mov Disord. 2016 May 2. doi: 10.1002/mds.26635.
    PubMed     Text format     Abstract available


  272. JABERI E, Rohani M, Shahidi GA, Nafissi S, et al
    Mutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction.
    Mov Disord. 2016 May 2. doi: 10.1002/mds.26627.
    PubMed     Text format     Abstract available


  273. YARNALL AJ, Lashley T, Ling H, Lees AJ, et al
    Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?
    Mov Disord. 2016;31:668-75.
    PubMed     Text format     Abstract available


    April 2016
  274. OLSZEWSKA DA, Lynch T
    MUL1-A new potential for a therapeutic target for Parkinson's disease a commentary on "MUL1 acts in parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss of PINK1/parkin" by Yun and colleagues (eLife 2014; 3: 1-26).
    Mov Disord. 2016 Apr 29. doi: 10.1002/mds.26652.
    PubMed     Text format    


  275. BROEN MP, Narayen NE, Kuijf ML, Dissanayaka NN, et al
    Prevalence of anxiety in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2016 Apr 29. doi: 10.1002/mds.26643.
    PubMed     Text format     Abstract available


  276. ESPAY AJ, Bonato P, Nahab FB, Maetzler W, et al
    Technology in Parkinson's disease: Challenges and opportunities.
    Mov Disord. 2016 Apr 29. doi: 10.1002/mds.26642.
    PubMed     Text format     Abstract available


  277. KANG UJ, Goldman JG, Alcalay RN, Xie T, et al
    The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.
    Mov Disord. 2016 Apr 26. doi: 10.1002/mds.26613.
    PubMed     Text format     Abstract available


  278. LOANE C, Politis M, Kefalopoulou Z, Valle-Guzman N, et al
    Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study.
    Mov Disord. 2016 Apr 22. doi: 10.1002/mds.26606.
    PubMed     Text format     Abstract available


  279. URIBE C, Segura B, Baggio HC, Abos A, et al
    Patterns of Cortical Thinning in Nondemented Parkinson's Disease Patients.
    Mov Disord. 2016 Apr 20. doi: 10.1002/mds.26590.
    PubMed     Text format     Abstract available


  280. ROSS GW, Petrovitch H, Abbott RD
    Serum vitamin D and risk of Parkinson's disease.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26639.
    PubMed     Text format    


  281. MCDONALD C, Newton JL, Burn DJ
    Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26632.
    PubMed     Text format     Abstract available


  282. ZHANG J, Nombela C, Wolpe N, Barker RA, et al
    Time on timing: Dissociating premature responding from interval sensitivity in Parkinson's disease.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26631.
    PubMed     Text format     Abstract available


  283. SCHAPIRA AH, Chiasserini D, Beccari T, Parnetti L, et al
    Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26616.
    PubMed     Text format     Abstract available


  284. MARRAS C, Alcalay RN, Caspell-Garcia C, Coffey C, et al
    Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26614.
    PubMed     Text format     Abstract available


  285. LEWITT PA, Hauser RA, Grosset DG, Stocchi F, et al
    A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26611.
    PubMed     Text format     Abstract available


  286. SHRESTHA S, Lutsey PL, Alonso A, Huang X, et al
    Serum 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26573.
    PubMed     Text format     Abstract available


  287. CAVINESS JN, Lue LF, Hentz JG, Schmitz CT, et al
    Cortical phosphorylated alpha-Synuclein levels correlate with brain wave spectra in Parkinson's disease.
    Mov Disord. 2016 Apr 8. doi: 10.1002/mds.26621.
    PubMed     Text format     Abstract available


  288. MARRAS C, Lang A, van de Warrenburg BP, Sue CM, et al
    Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force.
    Mov Disord. 2016;31:436-57.
    PubMed     Text format     Abstract available


  289. GREENE P
    Are more effective placebos complicating clinical trials?
    Mov Disord. 2016;31:606.
    PubMed     Text format    


  290. WEISS D, Herrmann S, Wang L, Schulte C, et al
    Alpha-synuclein gene variants may predict neurostimulation outcome.
    Mov Disord. 2016;31:601-3.
    PubMed     Text format    


  291. LAWTON M, Kasten M, May MT, Mollenhauer B, et al
    Validation of conversion between mini-mental state examination and montreal cognitive assessment.
    Mov Disord. 2016;31:593-6.
    PubMed     Text format     Abstract available


  292. LANG AE, Rodriguez RL, Boyd JT, Chouinard S, et al
    Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
    Mov Disord. 2016;31:538-46.
    PubMed     Text format     Abstract available


    March 2016
  293. FORLONI G, Artuso V, La Vitola P, Balducci C, et al
    Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases.
    Mov Disord. 2016 Mar 31. doi: 10.1002/mds.26624.
    PubMed     Text format     Abstract available


  294. WEINTRAUB D, Hauser RA, Elm JJ, Pagan F, et al
    Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
    Mov Disord. 2016 Mar 31. doi: 10.1002/mds.26617.
    PubMed     Text format     Abstract available


  295. ADLER CH, Beach TG
    Neuropathological basis of nonmotor manifestations of Parkinson's disease.
    Mov Disord. 2016 Mar 31. doi: 10.1002/mds.26605.
    PubMed     Text format     Abstract available


  296. COPELAND JN, Lieberman A, Oravivattanakul S, Troster AI, et al
    Accuracy of Patient and Care Partner Identification of Cognitive Impairments in Parkinson's Disease-Mild Cognitive Impairment.
    Mov Disord. 2016 Mar 29. doi: 10.1002/mds.26619.
    PubMed     Text format     Abstract available


  297. KLUGER BM, Rakowski D, Christian M, Cedar D, et al
    Randomized, Controlled Trial of Acupuncture for Fatigue in Parkinson's Disease.
    Mov Disord. 2016 Mar 29. doi: 10.1002/mds.26597.
    PubMed     Text format     Abstract available


  298. DE GERMAY S, Montastruc JL, Rousseau V, Chebane L, et al
    Atropinic (Anticholinergic) Burden in Parkinson's Disease.
    Mov Disord. 2016 Mar 29. doi: 10.1002/mds.26595.
    PubMed     Text format     Abstract available


  299. WILLIAMS-GRAY CH, Wijeyekoon R, Yarnall AJ, Lawson RA, et al
    Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).
    Mov Disord. 2016 Mar 21. doi: 10.1002/mds.26563.
    PubMed     Text format     Abstract available


  300. FLORES-CUADRADO A, Ubeda-Banon I, Saiz-Sanchez D, de la Rosa-Prieto C, et al
    Hippocampal alpha-synuclein and interneurons in Parkinson's disease: Data from human and mouse models.
    Mov Disord. 2016 Mar 18. doi: 10.1002/mds.26586.
    PubMed     Text format     Abstract available


  301. BAE YJ, Kim JM, Kim E, Lee KM, et al
    Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With I-FP-CIT SPECT.
    Mov Disord. 2016 Mar 17. doi: 10.1002/mds.26584.
    PubMed     Text format     Abstract available


  302. QUADRI M, Olgiati S, Sensi M, Gualandi F, et al
    PRKRA Mutation Causing Early-Onset Generalized Dystonia-Parkinsonism (DYT16) in an Italian Family.
    Mov Disord. 2016 Mar 17. doi: 10.1002/mds.26583.
    PubMed     Text format    


  303. NACKAERTS E, Heremans E, Vervoort G, Smits-Engelsman BC, et al
    Relearning of Writing Skills in Parkinson's Disease After Intensive Amplitude Training.
    Mov Disord. 2016 Mar 17. doi: 10.1002/mds.26565.
    PubMed     Text format     Abstract available


  304. BREEN DP, Nombela C, Vuono R, Jones PS, et al
    Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease.
    Mov Disord. 2016 Mar 12. doi: 10.1002/mds.26592.
    PubMed     Text format     Abstract available


  305. TAN B, Double KL, Burne J, Diong J, et al
    Tension-referenced measures of gastrocnemius slack length and stiffness in Parkinson's disease.
    Mov Disord. 2016 Mar 11. doi: 10.1002/mds.26530.
    PubMed     Text format     Abstract available


  306. HERZ DM, Haagensen BN, Nielsen SH, Madsen KH, et al
    Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
    Mov Disord. 2016 Mar 8. doi: 10.1002/mds.26540.
    PubMed     Text format     Abstract available


  307. VICENTE MIRANDA H, El-Agnaf OM, Outeiro TF
    Glycation in Parkinson's disease and Alzheimer's disease.
    Mov Disord. 2016 Mar 4. doi: 10.1002/mds.26566.
    PubMed     Text format     Abstract available


  308. RICCIARDI L, Bove F, Espay KJ, Lena F, et al
    24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
    Mov Disord. 2016 Mar 4. doi: 10.1002/mds.26564.
    PubMed     Text format    


  309. BLOEM BR, Marinus J, Almeida Q, Dibble L, et al
    Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations.
    Mov Disord. 2016 Mar 4. doi: 10.1002/mds.26572.
    PubMed     Text format     Abstract available



  310. Corrigenda: Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase.
    Mov Disord. 2016;31:433.
    PubMed     Text format    



  311. Abstracts of the Fifth Asian and Oceanian Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2016;31 Suppl 1:S1-S103.
    PubMed     Text format    


  312. HERNANDEZ LF
    An A-PLAuse to a new assay that unveils previously undetected alpha-synucleinopathies.
    Mov Disord. 2016;31:301.
    PubMed     Text format    


  313. SWALLOW DM, Grosset KA, Grosset DG
    Nonmotor symptoms in patients without evidence of dopaminergic deficit.
    Mov Disord. 2016;31:429-30.
    PubMed     Text format    


  314. SPRENGER FS, Seppi K, Djamshidian A, Poewe W, et al
    Reply to "Nonmotor symptoms in subjects without evidence of dopaminergic deficit" authors: "Swallow DMA, Grosset KA, Grosset DG".
    Mov Disord. 2016;31:430-1.
    PubMed     Text format    


  315. MESTRE TA, Lang AE, Okun MS
    Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.
    Mov Disord. 2016;31:290-6.
    PubMed     Text format     Abstract available


  316. OROPESA-RUIZ JM, Huertas-Fernandez I, Jesus S, Caceres-Redondo MT, et al
    Low serum uric acid levels in progressive supranuclear palsy.
    Mov Disord. 2016;31:402-5.
    PubMed     Text format     Abstract available


  317. WILE DJ, Dinelle K, Vafai N, McKenzie J, et al
    A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.
    Mov Disord. 2016;31:405-9.
    PubMed     Text format     Abstract available


  318. WALTER U, Muller JU, Rosche J, Kirsch M, et al
    Magnetic resonance-transcranial ultrasound fusion imaging: A novel tool for brain electrode location.
    Mov Disord. 2016;31:302-9.
    PubMed     Text format     Abstract available


    February 2016
  319. MOORS T, Paciotti S, Chiasserini D, Calabresi P, et al
    Lysosomal Dysfunction and alpha-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links.
    Mov Disord. 2016 Feb 29. doi: 10.1002/mds.26562.
    PubMed     Text format     Abstract available


  320. NOWINSKI CJ, Siderowf A, Simuni T, Wortman C, et al
    Neuro-QoL health-related quality of life measurement system: Validation in Parkinson's disease.
    Mov Disord. 2016 Feb 26. doi: 10.1002/mds.26546.
    PubMed     Text format     Abstract available


  321. FIORENTINI C, Savoia P, Savoldi D, Bono F, et al
    Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
    Mov Disord. 2016 Feb 22. doi: 10.1002/mds.26581.
    PubMed     Text format     Abstract available


  322. BERG D, Postuma RB
    Diagnosis of Parkinson's disease: Imaging and genetics.
    Mov Disord. 2016 Feb 22. doi: 10.1002/mds.26544.
    PubMed     Text format    


  323. ERRO R, Bhatia KP
    Novel movement disorder society-Parkinson's disease criteria: What about SWEDD and genetic forms?
    Mov Disord. 2016 Feb 19. doi: 10.1002/mds.26538.
    PubMed     Text format    


  324. SPRENGER FS, Wurster I, Seppi K, Stockner H, et al
    Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor.
    Mov Disord. 2016 Feb 19. doi: 10.1002/mds.26515.
    PubMed     Text format     Abstract available


  325. NAVNTOFT CA, Dreyer JK
    How compensation breaks down in Parkinson's disease: Insights from modeling of denervated striatum.
    Mov Disord. 2016 Feb 18. doi: 10.1002/mds.26579.
    PubMed     Text format     Abstract available


  326. MANENTI R, Brambilla M, Benussi A, Rosini S, et al
    Mild cognitive impairment in Parkinson's disease is improved by transcranial direct current stimulation combined with physical therapy.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26561.
    PubMed     Text format     Abstract available


  327. MULLER T, Kohlhepp W
    Hypomethylation in Parkinson's disease: An epigenetic drug effect?
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26560.
    PubMed     Text format    


  328. KLETTNER A, Richert E, Kuhlenbaumer G, Nolle B, et al
    Alpha synuclein and crystallin expression in human lens in Parkinson's disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26557.
    PubMed     Text format    


  329. CALIGIURI ME, Nistico R, Arabia G, Morelli M, et al
    Alterations of putaminal shape in de novo Parkinson's disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26550.
    PubMed     Text format     Abstract available


  330. ADLER CH, Hentz JG, Beach TG
    Assessing medication role on neuropathological findings in Parkinson's disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26536.
    PubMed     Text format    


  331. PALMA JA, Norcliffe-Kaufmann L, Kaufmann H
    An orthostatic hypotension mimic: The inebriation-like syndrome in Parkinson disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26516.
    PubMed     Text format    


  332. KLUGER BM, Herlofson K, Chou KL, Lou JS, et al
    Parkinson's disease-related fatigue: A case definition and recommendations for clinical research.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26511.
    PubMed     Text format     Abstract available


  333. HALL S, Surova Y, Ohrfelt A, Blennow K, et al
    Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26578.
    PubMed     Text format     Abstract available


  334. RANGO M, Piatti M, Di Fonzo A, Ardolino G, et al
    Abnormal brain temperature in early-onset Parkinson's disease.
    Mov Disord. 2016 Feb 13. doi: 10.1002/mds.26548.
    PubMed     Text format    


  335. DING C, Ganesvaran G, Alty JE, Clissold BG, et al
    Study of levodopa response in Parkinson's disease: Observations on rates of motor progression.
    Mov Disord. 2016 Feb 13. doi: 10.1002/mds.26497.
    PubMed     Text format     Abstract available


  336. PINNA A, Ko WK, Costa G, Tronci E, et al
    Antidyskinetic effect of A and 5HT receptor ligands in two animal models of Parkinson's disease.
    Mov Disord. 2016 Feb 12. doi: 10.1002/mds.26475.
    PubMed     Text format     Abstract available


  337. TAYLOR S, Gafton J, Shah B, Pagano G, et al
    Progression of nonmotor symptoms in subgroups of patients with non-dopamine-deficient Parkinsonism.
    Mov Disord. 2016 Feb 11. doi: 10.1002/mds.26456.
    PubMed     Text format     Abstract available


  338. SOMEKO H, Hanajima R, Tsutsumi R, Tominaga N, et al
    Abnormal myocardial scintigraphy in a GTP cyclohydrolase 1 mutation carrier with Parkinson's disease.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26523.
    PubMed     Text format    


  339. MARRAS C, Chaudhuri KR
    Nonmotor features of Parkinson's disease subtypes.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26510.
    PubMed     Text format     Abstract available


  340. CASTELA I
    GABA: Inhibition brings new excitement in Parkinson's disease.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26507.
    PubMed     Text format    


  341. MOELTER ST, Weintraub D, Mace L, Cary M, et al
    Research consent capacity varies with executive function and memory in Parkinson's disease.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26469.
    PubMed     Text format     Abstract available


  342. CARR J, Guella I, Szu-Tu C, Boolay S, et al
    Double homozygous mutations (R275W and M432V) in the ParkinGene associated with late-onset Parkinson's disease.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26524.
    PubMed     Text format    


  343. GATT AP, Duncan OF, Attems J, Francis PT, et al
    Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency.
    Mov Disord. 2016 Feb 8. doi: 10.1002/mds.26513.
    PubMed     Text format     Abstract available


  344. PIHLSTROM L, Morset KR, Grimstad E, Vitelli V, et al
    A cumulative genetic risk score predicts progression in Parkinson's disease.
    Mov Disord. 2016 Feb 8. doi: 10.1002/mds.26505.
    PubMed     Text format     Abstract available


  345. ZHANG P, Shao XY, Qi GJ, Chen Q, et al
    Cdk5-Dependent Activation of Neuronal Inflammasomes in Parkinson's Disease.
    Mov Disord. 2016 Feb 8. doi: 10.1002/mds.26488.
    PubMed     Text format     Abstract available


  346. LEE JY, Yun EJ, Lee WW, Kim YK, et al
    Lateral geniculate atrophy in Parkinson's with visual hallucination: A trans-synaptic degeneration?
    Mov Disord. 2016 Feb 5. doi: 10.1002/mds.26533.
    PubMed     Text format     Abstract available


  347. MCINTOSH E, Gray A, Daniels J, Gill S, et al
    Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trial.
    Mov Disord. 2016 Feb 5. doi: 10.1002/mds.26423.
    PubMed     Text format     Abstract available


  348. STEFANOVA N, Kordower JH, Wenning GK
    Preface.
    Mov Disord. 2016;31:151.
    PubMed     Text format    


  349. RICCIARDI L, Petrucci S, Di Giuda D, Serra L, et al
    The Contursi Family 20 Years Later: Intrafamilial Phenotypic Variability of the SNCA p.A53T Mutation.
    Mov Disord. 2016;31:257-8.
    PubMed     Text format    


  350. RUFFMANN C, Parkkinen L
    Gut Feelings About alpha-Synuclein in Gastrointestinal Biopsies: Biomarker in the Making?
    Mov Disord. 2016;31:193-202.
    PubMed     Text format     Abstract available


  351. CALO L, Wegrzynowicz M, Santivanez-Perez J, Grazia Spillantini M, et al
    Synaptic failure and alpha-synuclein.
    Mov Disord. 2016;31:169-77.
    PubMed     Text format     Abstract available


  352. BERGSTROM AL, Kallunki P, Fog K
    Development of Passive Immunotherapies for Synucleinopathies.
    Mov Disord. 2016;31:203-13.
    PubMed     Text format     Abstract available


  353. VALERA E, Masliah E
    Combination therapies: The next logical Step for the treatment of synucleinopathies?
    Mov Disord. 2016;31:225-34.
    PubMed     Text format     Abstract available


  354. MCCANN H, Cartwright H, Halliday GM
    Neuropathology of alpha-synuclein propagation and braak hypothesis.
    Mov Disord. 2016;31:152-60.
    PubMed     Text format     Abstract available


  355. SCHNEEBERGER A, Tierney L, Mandler M
    Active immunization therapies for Parkinson's disease and multiple system atrophy.
    Mov Disord. 2016;31:214-24.
    PubMed     Text format     Abstract available


    January 2016
  356. VIDENOVIC A, Willis GL
    Circadian system - A novel diagnostic and therapeutic target in Parkinson's disease?
    Mov Disord. 2016 Jan 30. doi: 10.1002/mds.26509.
    PubMed     Text format     Abstract available


  357. ANTONINI A, Fung VS, Boyd JT, Slevin JT, et al
    Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Mov Disord. 2016 Jan 28. doi: 10.1002/mds.26528.
    PubMed     Text format     Abstract available


  358. MALEKMOHAMMADI M, Herron J, Velisar A, Blumenfeld Z, et al
    Kinematic Adaptive Deep Brain Stimulation for Resting Tremor in Parkinson's Disease.
    Mov Disord. 2016 Jan 27. doi: 10.1002/mds.26482.
    PubMed     Text format    


  359. XILOURI M, Brekk OR, Stefanis L
    Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
    Mov Disord. 2016 Jan 27. doi: 10.1002/mds.26477.
    PubMed     Text format     Abstract available


  360. BHATTACHARYYA S, Bakshi R, Logan R, Ascherio A, et al
    Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease.
    Mov Disord. 2016 Jan 25. doi: 10.1002/mds.26483.
    PubMed     Text format     Abstract available


  361. ADLER CH, Dugger BN, Hentz JG, Hinni ML, et al
    Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings.
    Mov Disord. 2016 Jan 22. doi: 10.1002/mds.26476.
    PubMed     Text format     Abstract available


  362. CAKMAK YO
    Coffee consumption, smoking, and Parkinson's disease? The beneficial role of hydrogen sulfide.
    Mov Disord. 2016 Jan 14. doi: 10.1002/mds.26526.
    PubMed     Text format    


  363. MACEROLLO A, Chen JC, Korlipara P, Foltynie T, et al
    Dopaminergic treatment modulates sensory attenuation at the onset of the movement in Parkinson's disease: A test of a new framework for bradykinesia.
    Mov Disord. 2016 Jan 9. doi: 10.1002/mds.26493.
    PubMed     Text format     Abstract available


  364. SAITO Y, Shioya A, Sano T, Sumikura H, et al
    Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders.
    Mov Disord. 2016 Jan 8. doi: 10.1002/mds.26463.
    PubMed     Text format     Abstract available


  365. CARTA M, Cenci MA
    On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
    Mov Disord. 2016;31:149.
    PubMed     Text format    


  366. OLANOW CW, Poewe W
    Eldad Melamed 1942-2015: Ave atque--A memorial.
    Mov Disord. 2016;31:39-40.
    PubMed     Text format    


    December 2015
  367. REYNOLDS GO, Otto MW, Ellis TD, Cronin-Golomb A, et al
    The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.
    Mov Disord. 2015 Dec 30. doi: 10.1002/mds.26484.
    PubMed     Text format     Abstract available


  368. NOYCE AJ, Nalls MA
    Mendelian Randomization - the Key to Understanding Aspects of Parkinson's Disease Causation?
    Mov Disord. 2015 Dec 23. doi: 10.1002/mds.26492.
    PubMed     Text format     Abstract available


  369. MARTINEZ-MARTIN P, Leentjens AF, de Pedro-Cuesta J, Chaudhuri KR, et al
    Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease.
    Mov Disord. 2015 Dec 22. doi: 10.1002/mds.26522.
    PubMed     Text format     Abstract available


  370. WILLIAMS-GRAY CH
    A new biomarker for Parkinson's disease?
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26448.
    PubMed     Text format    


  371. FOO JN, Chung SJ, Tan LC, Liany H, et al
    Linking a genome-wide association study signal to a LRRK2 coding variant in Parkinson's disease.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26495.
    PubMed     Text format     Abstract available


  372. BERGARECHE A, Rodriguez-Oroz MC, Estanga A, Gorostidi A, et al
    DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26478.
    PubMed     Text format     Abstract available


  373. CHUNG SJ, Kim J, Lee HJ, Ryu HS, et al
    Alpha-synuclein in gastric and colonic mucosa in Parkinson's disease: Limited role as a biomarker.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26473.
    PubMed     Text format     Abstract available


  374. BROEN MP, Kohler S, Moonen AJ, Kuijf ML, et al
    Modeling anxiety in Parkinson's disease.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26461.
    PubMed     Text format     Abstract available


  375. UDUPA K, Chen R
    Role of dopamine in motor cortex plasticity in Parkinson's disease.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26451.
    PubMed     Text format    


  376. BARBAGALLO G, Sierra-Pena M, Nemmi F, Traon AP, et al
    Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease.
    Mov Disord. 2015 Dec 17. doi: 10.1002/mds.26471.
    PubMed     Text format     Abstract available


  377. DE VRIES NM, Nonnekes J, Bloem BR
    Toward affordable falls prevention in Parkinson's disease.
    Mov Disord. 2015 Dec 11. doi: 10.1002/mds.26474.
    PubMed     Text format    


  378. FRIEDMAN JH
    Editorial on: Pagonabarraga J, Martinez-Hora S, Fernandez de Bobadilla R et al. Minor hallucinations occur in drug-naive Parkinson's disease patients even from the premotor phase. Movement Disorders 2015; Available from: DOI: 10.1002/mds.26432.
    Mov Disord. 2015 Dec 11. doi: 10.1002/mds.26472.
    PubMed     Text format    


  379. BOEL JA, Odekerken VJ, Geurtsen GJ, Schmand BA, et al
    Psychiatric and social outcome after deep brain stimulation for advanced Parkinson's disease.
    Mov Disord. 2015 Dec 11. doi: 10.1002/mds.26468.
    PubMed     Text format     Abstract available


  380. SHUAIB UA, Rajput AH, Robinson CA, Rajput A, et al
    Neuroleptic-induced Parkinsonism: Clinicopathological study.
    Mov Disord. 2015 Dec 11. doi: 10.1002/mds.26467.
    PubMed     Text format     Abstract available


  381. DIEDERICH NJ, Goldman JG, Stebbins GT, Goetz CG, et al
    Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease.
    Mov Disord. 2015 Dec 9. doi: 10.1002/mds.26460.
    PubMed     Text format     Abstract available


  382. HENTZ JG, Mehta SH, Shill HA, Driver-Dunckley E, et al
    Simplified conversion method for unified Parkinson's disease rating scale motor examinations.
    Mov Disord. 2015;30:1967-70.
    PubMed     Text format     Abstract available


    November 2015
  383. SWANSON CR, Alcalay RN, Chen-Plotkin A
    Reply to letter: Plasma fasting cholesterol profiles and age at onset in Parkinson's disease.
    Mov Disord. 2015 Nov 19. doi: 10.1002/mds.26447.
    PubMed     Text format    


  384. MASTERS JM, Bestwick J, Warner TT, Giovannoni G, et al
    Systematic review and meta-analysis of salivary protein concentration in Parkinson's disease.
    Mov Disord. 2015 Nov 19. doi: 10.1002/mds.26462.
    PubMed     Text format    


  385. MAHLKNECHT P, Sprenger F, Seppi K, Poewe W, et al
    Plasma fasting cholesterol profiles and age at onset in Parkinson's disease.
    Mov Disord. 2015 Nov 19. doi: 10.1002/mds.26452.
    PubMed     Text format    


  386. ERRO R, Barone P
    Toward the premotor diagnosis of Parkinson's disease: Suggestions from a modelling study.
    Mov Disord. 2015 Nov 17. doi: 10.1002/mds.26440.
    PubMed     Text format    


  387. KOJOVIC M, Bologna M, Edwards MJ, Rothwell JC, et al
    Reply to "Transcranial Magnetic Stimulation for Parkinson's Disease".
    Mov Disord. 2015 Nov 17. doi: 10.1002/mds.26441.
    PubMed     Text format    


  388. VAN DEN NOORT M, Bosch P, Yeo S, Lim S, et al
    Transcranial Magnetic Stimulation for Parkinson's Disease.
    Mov Disord. 2015 Nov 17. doi: 10.1002/mds.26439.
    PubMed     Text format    


  389. NICOLETTI A, Zappia M
    Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson's disease: The FRAGAMP study.
    Mov Disord. 2015;30:1854-6.
    PubMed     Text format    


  390. PAPAGIANNAKIS N, Xilouri M, Koros C, Stamelou M, et al
    Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients.
    Mov Disord. 2015;30:1830-4.
    PubMed     Text format     Abstract available


  391. LIM TT, Kluger BM, Rodriguez RL, Malaty IA, et al
    Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease.
    Mov Disord. 2015;30:1825-30.
    PubMed     Text format     Abstract available


  392. FUNG VS, Kordower JH
    Parkinson's disease and prion disease: Straining the comparison.
    Mov Disord. 2015;30:1727.
    PubMed     Text format    


  393. OLANOW CW, Bartus RT, Volpicelli-Daley LA, Kordower JH, et al
    Trophic factors for Parkinson's disease: To live or let die.
    Mov Disord. 2015;30:1715-24.
    PubMed     Text format     Abstract available


    October 2015
  394. SOLLA P, Fasano A, Cannas A, Marrosu F, et al
    Suicide and dopamine agonist withdrawal syndrome in Parkinson's disease.
    Mov Disord. 2015 Oct 10. doi: 10.1002/mds.26443.
    PubMed     Text format    


  395. ROSENTHAL LS, Drake D, Alcalay RN, Babcock D, et al
    The NINDS Parkinson's disease biomarkers program.
    Mov Disord. 2015 Oct 7. doi: 10.1002/mds.26438.
    PubMed     Text format     Abstract available


  396. BERG D, Postuma RB, Adler CH, Bloem BR, et al
    MDS research criteria for prodromal Parkinson's disease.
    Mov Disord. 2015;30:1600-11.
    PubMed     Text format     Abstract available


  397. POSTUMA RB, Berg D, Stern M, Poewe W, et al
    MDS clinical diagnostic criteria for Parkinson's disease.
    Mov Disord. 2015;30:1591-601.
    PubMed     Text format     Abstract available


  398. VAN STEENOVEN I, Aarsland D, Weintraub D
    Reply to letter to the editor 'Independent application of MoCA/MMSE conversion' by Armstrong et al.
    Mov Disord. 2015;30:1711.
    PubMed     Text format    


  399. ARMSTRONG MJ, Duff-Canning S, Psych C, Kowgier M, et al
    Independent application of montreal cognitive assessment/mini-mental state examination conversion.
    Mov Disord. 2015;30:1710-1.
    PubMed     Text format    


    September 2015
  400. PAGONABARRAGA J, Martinez-Horta S, Fernandez de Bobadilla R, Perez J, et al
    Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase.
    Mov Disord. 2015 Sep 26. doi: 10.1002/mds.26432.
    PubMed     Text format     Abstract available


  401. HAM JH, Lee JJ, Kim JS, Lee PH, et al
    Is Dominant-Side Onset Associated With a Better Motor Compensation in Parkinson's Disease?
    Mov Disord. 2015 Sep 26. doi: 10.1002/mds.26418.
    PubMed     Text format     Abstract available


  402. FARAG I, Sherrington C, Hayes A, Canning CG, et al
    Economic evaluation of a falls prevention exercise program among people With Parkinson's disease.
    Mov Disord. 2015 Sep 23. doi: 10.1002/mds.26420.
    PubMed     Text format     Abstract available


  403. SHAH N, Frey KA, L T M Muller M, Petrou M, et al
    Striatal and Cortical beta-Amyloidopathy and Cognition in Parkinson's Disease.
    Mov Disord. 2015 Sep 18. doi: 10.1002/mds.26369.
    PubMed     Text format     Abstract available


  404. SCHRAG A, Sauerbier A, Chaudhuri KR
    New clinical trials for nonmotor manifestations of Parkinson's disease.
    Mov Disord. 2015;30:1490-504.
    PubMed     Text format     Abstract available


  405. DU G, Liu T, Lewis MM, Kong L, et al
    Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
    Mov Disord. 2015 Sep 12. doi: 10.1002/mds.26417.
    PubMed     Text format     Abstract available


  406. QUINN EJ, Blumenfeld Z, Velisar A, Koop MM, et al
    Beta oscillations in freely moving Parkinson's subjects are attenuated during deep brain stimulation.
    Mov Disord. 2015 Sep 11. doi: 10.1002/mds.26376.
    PubMed     Text format     Abstract available


  407. SLOTNICK S, Ding Y, Glazman S, Durbin M, et al
    A novel retinal biomarker for Parkinson's disease: Quantifying the foveal pit with optical coherence tomography.
    Mov Disord. 2015 Sep 4. doi: 10.1002/mds.26411.
    PubMed     Text format     Abstract available


    August 2015
  408. GOLDMAN JG, Weintraub D
    Advances in the treatment of cognitive impairment in Parkinson's disease.
    Mov Disord. 2015 Aug 22. doi: 10.1002/mds.26352.
    PubMed     Text format     Abstract available


  409. MATA IF, Leverenz JB, Weintraub D, Trojanowski JQ, et al
    GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.
    Mov Disord. 2015 Aug 21. doi: 10.1002/mds.26359.
    PubMed     Text format     Abstract available


  410. CHAHINE LM, Weintraub D, Hawkins KA, Siderowf A, et al
    Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings.
    Mov Disord. 2015 Aug 21. doi: 10.1002/mds.26373.
    PubMed     Text format     Abstract available


  411. CERASA A, Donzuso G, Morelli M, Mangone G, et al
    The motor inhibition system in Parkinson's disease with levodopa-induced dyskinesias.
    Mov Disord. 2015 Aug 14. doi: 10.1002/mds.26378.
    PubMed     Text format     Abstract available


  412. BLOEM BR, de Vries NM, Ebersbach G
    Nonpharmacological treatments for patients with Parkinson's disease.
    Mov Disord. 2015 Aug 14. doi: 10.1002/mds.26363.
    PubMed     Text format     Abstract available


  413. METMAN LV, Slavin KV
    Advances in functional neurosurgery for Parkinson's disease.
    Mov Disord. 2015 Aug 14. doi: 10.1002/mds.26338.
    PubMed     Text format     Abstract available


  414. NALLS MA, Keller MF, Hernandez DG, Chen L, et al
    Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI).
    Mov Disord. 2015 Aug 13. doi: 10.1002/mds.26374.
    PubMed     Text format     Abstract available


  415. POSTUMA RB, Adler CH, Dugger BN, Hentz JG, et al
    REM sleep behavior disorder and neuropathology in Parkinson's disease.
    Mov Disord. 2015 Aug 12. doi: 10.1002/mds.26347.
    PubMed     Text format     Abstract available


  416. RAJ KUMAR K
    Targeting glucocerebrosidase: Reduced enzymatic activity and Parkinson's disease.
    Mov Disord. 2015 Aug 11. doi: 10.1002/mds.26379.
    PubMed     Text format    


  417. SCHUFF N, Wu IW, Buckley S, Foster ED, et al
    Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits.
    Mov Disord. 2015 Aug 11. doi: 10.1002/mds.26325.
    PubMed     Text format     Abstract available


  418. BRENNAN L, Siderowf A, Rubright JD, Rick J, et al
    Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire.
    Mov Disord. 2015 Aug 7. doi: 10.1002/mds.26339.
    PubMed     Text format     Abstract available


  419. PIHLSTROM L, Toft M
    Cumulative genetic risk and age at onset in Parkinson's disease.
    Mov Disord. 2015 Aug 3. doi: 10.1002/mds.26366.
    PubMed     Text format    


  420. VIRMANI T, Moskowitz CB, Vonsattel JP, Fahn S, et al
    Clinicopathological characteristics of freezing of gait in autopsy-confirmed Parkinson's disease.
    Mov Disord. 2015 Aug 3. doi: 10.1002/mds.26346.
    PubMed     Text format     Abstract available


  421. MA Y, Johnston TH, Peng S, Zuo C, et al
    Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.
    Mov Disord. 2015;30:1283-8.
    PubMed     Text format     Abstract available


    July 2015
  422. SCHRAG A
    A new scale for the assessment of pain in Parkinson's disease.
    Mov Disord. 2015 Jul 31. doi: 10.1002/mds.26353.
    PubMed     Text format    


  423. MISCHLEY LK, Leverenz JB, Lau RC, Polissar NL, et al
    A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.
    Mov Disord. 2015 Jul 31. doi: 10.1002/mds.26351.
    PubMed     Text format     Abstract available


  424. SERAJI-BOZORGZAD N, Bao F, George E, Krstevska S, et al
    Longitudinal study of the substantia nigra in Parkinson disease: A high-field H-MR spectroscopy imaging study.
    Mov Disord. 2015 Jul 31. doi: 10.1002/mds.26323.
    PubMed     Text format     Abstract available


  425. GESQUIERE-DANDO A, Guedj E, Loundou A, Carron R, et al
    A preoperative metabolic marker of parkinsonian apathy following subthalamic nucleus stimulation.
    Mov Disord. 2015 Jul 31. doi: 10.1002/mds.26349.
    PubMed     Text format     Abstract available


  426. UDUPA K, Ghahremani A, Chen R
    Are we close to the advent of closed loop deep brain stimulation in Parkinson's disease?
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26343.
    PubMed     Text format    


  427. MENDES A, Goncalves A, Vila-Cha N, Moreira I, et al
    Appendectomy may delay Parkinson's disease Onset.
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26311.
    PubMed     Text format     Abstract available


  428. RAMIREZ A
    Population-Based Genetic Studies: The Search for Causative Variants in Parkinson's Disease.
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26341.
    PubMed     Text format    


  429. POSTUMA RB
    Can Parkinson's Disease Come From the Gut?
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26337.
    PubMed     Text format    


  430. WILLIAMS-GRAY C
    Seeing Is Believing: Alpha-Synuclein Oligomers in Parkinson's Disease Brain.
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26335.
    PubMed     Text format    


  431. KALIA LV, Kalia SK, Lang AE
    Disease-modifying strategies for Parkinson's disease.
    Mov Disord. 2015 Jul 24. doi: 10.1002/mds.26354.
    PubMed     Text format     Abstract available


  432. SWANSON CR, Berlyand Y, Xie SX, Alcalay RN, et al
    Plasma Apolipoprotein A1 Associates With Age at Onset and Motor Severity in Early Parkinson's Disease Patients.
    Mov Disord. 2015 Jul 24. doi: 10.1002/mds.26290.
    PubMed     Text format     Abstract available


  433. DUNCAN GW, Firbank MJ, Yarnall AJ, Khoo TK, et al
    Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease?
    Mov Disord. 2015 Jul 22. doi: 10.1002/mds.26312.
    PubMed     Text format     Abstract available


  434. REHMAN AF, Dhamija R, Williams ES, Barrett MJ, et al
    22q11.2 deletion syndrome presenting with early-onset Parkinson's disease.
    Mov Disord. 2015 Jul 21. doi: 10.1002/mds.26305.
    PubMed     Text format    


  435. OZ G
    MR Spectroscopy: A Longitudinal Biomarker for Substantia Nigra Pathology in Parkinson's Disease?
    Mov Disord. 2015 Jul 17. doi: 10.1002/mds.26322.
    PubMed     Text format    


  436. ZORKO N, Kojovic M, Flisar D, Pirtosek Z, et al
    Suicide in Parkinson's Disease Patients Treated With Levodopa-Carbidopa Intestinal Gel.
    Mov Disord. 2015 Jul 17. doi: 10.1002/mds.26315.
    PubMed     Text format    


  437. LOU Y, Huang P, Li D, Cen Z, et al
    Altered brain network centrality in depressed Parkinson's disease patients.
    Mov Disord. 2015 Jul 16. doi: 10.1002/mds.26321.
    PubMed     Text format     Abstract available


  438. FERNANDEZ HH, Standaert DG, Chatamra K, Benesh JA, et al
    Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal Gel.
    Mov Disord. 2015 Jul 16. doi: 10.1002/mds.26316.
    PubMed     Text format    


  439. KESHAVARZIAN A, Green SJ, Engen PA, Voigt RM, et al
    Colonic bacterial composition in Parkinson's disease.
    Mov Disord. 2015 Jul 16. doi: 10.1002/mds.26307.
    PubMed     Text format     Abstract available


  440. BRUNDIN P, Atkin G, Lamberts JT
    Basic science breaks through: New therapeutic advances in Parkinson's disease.
    Mov Disord. 2015 Jul 16. doi: 10.1002/mds.26332.
    PubMed     Text format     Abstract available


  441. LOPANE G, Mellone S, Chiari L, Cortelli P, et al
    Dyskinesia detection and monitoring by a single sensor in patients with Parkinson's disease.
    Mov Disord. 2015 Jul 14. doi: 10.1002/mds.26313.
    PubMed     Text format     Abstract available


  442. BAIG F, Lawton M, Rolinski M, Ruffmann C, et al
    Delineating nonmotor symptoms in early Parkinson's disease and first-degree relatives.
    Mov Disord. 2015 Jul 14. doi: 10.1002/mds.26281.
    PubMed     Text format     Abstract available


  443. SCHMITT I, Kaut O, Khazneh H, deBoni L, et al
    L-dopa increases alpha-synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro.
    Mov Disord. 2015 Jul 14. doi: 10.1002/mds.26319.
    PubMed     Text format     Abstract available


  444. STEELE JC, Wresch R, Hanlon SD, Keystone J, et al
    A unique retinal epitheliopathy is associated with amyotrophic lateral sclerosis/Parkinsonism-Dementia complex of Guam.
    Mov Disord. 2015 Jul 7. doi: 10.1002/mds.26264.
    PubMed     Text format     Abstract available


  445. SANTANGELO G, Trojano L, Barone P, Vitale C, et al
    Cortical thickness in Parkinsonians with impulse control disorders: A comment.
    Mov Disord. 2015 Jul 7. doi: 10.1002/mds.26262.
    PubMed     Text format    


  446. BURCIU RG, Ofori E, Shukla P, Planetta PJ, et al
    Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2015 Jul 6. doi: 10.1002/mds.26294.
    PubMed     Text format     Abstract available


  447. DAVID FJ, Robichaud JA, Leurgans SE, Poon C, et al
    Exercise Improves Cognition in Parkinson's Disease: The PRET-PD Randomized, Clinical Trial.
    Mov Disord. 2015 Jul 6. doi: 10.1002/mds.26291.
    PubMed     Text format     Abstract available


  448. SCHEPERJANS F
    Reply to letter to the editor by Assoc. Prof. Yusuf Ozgur Cakmak, MD, PhD.
    Mov Disord. 2015;30:1151-3.
    PubMed     Text format    


    June 2015
  449. CURTZE C, Nutt JG, Carlson-Kuhta P, Mancini M, et al
    Levodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson's Disease.
    Mov Disord. 2015 Jun 12. doi: 10.1002/mds.26269.
    PubMed     Text format     Abstract available


  450. MURATA M, Hasegawa K, Kanazawa I, Fukasaka J, et al
    Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
    Mov Disord. 2015 Jun 12. doi: 10.1002/mds.26286.
    PubMed     Text format     Abstract available


  451. FRANCIOTTI R, Delli Pizzi S, Perfetti B, Tartaro A, et al
    Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy.
    Mov Disord. 2015 Jun 12. doi: 10.1002/mds.26285.
    PubMed     Text format     Abstract available


  452. GEGG ME, Sweet L, Wang BH, Shihabuddin LS, et al
    No evidence for substrate accumulation in Parkinson brains with GBA mutations.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26278.
    PubMed     Text format     Abstract available


  453. ROCHESTER L, Espay AJ
    Multidisciplinary rehabilitation in Parkinson's disease: A milestone with future challenges.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26277.
    PubMed     Text format    


  454. ROSSI M, Perez-Lloret S, Millar Vernetti P, Drucaroff L, et al
    Olfactory Dysfunction Evaluation Is Not Affected by Comorbid Depression in Parkinson's Disease.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26276.
    PubMed     Text format     Abstract available


  455. FORJAZ MJ, Ayala A, Testa CM, Bain PG, et al
    Proposing a Parkinson's Disease-Specific Tremor Scale From the MDS-UPDRS.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26271.
    PubMed     Text format     Abstract available


  456. CHAUDHURI KR, Rizos A, Trenkwalder C, Rascol O, et al
    King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26270.
    PubMed     Text format     Abstract available


  457. WAKEMAN DR
    Autologous iPSC-Derived Dopamine Neuron Grafts Show Considerable Promise in a Nonhuman Primate Model of Parkinson's Disease.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26267.
    PubMed     Text format    


  458. MONTICONE M, Ambrosini E, Laurini A, Rocca B, et al
    In-patient multidisciplinary rehabilitation for Parkinson's disease: A randomized controlled trial.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26256.
    PubMed     Text format     Abstract available


  459. CERAVOLO R, Antonini A, Frosini D, De Iuliis A, et al
    Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26255.
    PubMed     Text format    


  460. SIMUNI T, Caspell-Garcia C, Coffey C, Chahine LM, et al
    Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26248.
    PubMed     Text format     Abstract available


  461. KOTAGAL V, Bohnen NI, Muller ML, Koeppe RA, et al
    Educational Attainment and Motor Burden in Parkinson's Disease.
    Mov Disord. 2015 Jun 10. doi: 10.1002/mds.26272.
    PubMed     Text format     Abstract available



  462. Abstracts of the Nineteenth International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2015;30 Suppl 1:S1-S642.
    PubMed     Text format    


  463. HORNYKIEWICZ O
    50 years of levodopa.
    Mov Disord. 2015;30:1008.
    PubMed     Text format    


  464. FAHN S
    Reply: Oleh Hornykiewicz's contribution to the l-dopa story.
    Mov Disord. 2015;30:1008-9.
    PubMed     Text format    


    May 2015
  465. CARECCHIO M, Schneider SA
    GTP cyclohydrolase 1 mutations and Parkinson's disease: New insights beyond DOPA-responsive dystonia.
    Mov Disord. 2015 May 27. doi: 10.1002/mds.26283.
    PubMed     Text format    


  466. BURN DJ
    The treatment of mild cognitive impairment associated with Parkinson's.
    Mov Disord. 2015 May 23. doi: 10.1002/mds.26245.
    PubMed     Text format    


  467. LOHMANN E, Coquel AS, Honore A, Gurvit H, et al
    A new F-box protein 7 gene mutation causing typical Parkinson's disease.
    Mov Disord. 2015 May 23. doi: 10.1002/mds.26266.
    PubMed     Text format     Abstract available


  468. ROSA M, Arlotti M, Ardolino G, Cogiamanian F, et al
    Adaptive deep brain stimulation in a freely moving parkinsonian patient.
    Mov Disord. 2015 May 21. doi: 10.1002/mds.26241.
    PubMed     Text format    


  469. VIZCARRA JA, Lang AE, Sethi KD, Espay AJ, et al
    Vascular Parkinsonism: Deconstructing a Syndrome.
    Mov Disord. 2015 May 21. doi: 10.1002/mds.26263.
    PubMed     Text format     Abstract available


  470. CAKMAK YO
    Provotella-derived hydrogen sulfide, constipation, and neuroprotection in Parkinson's disease.
    Mov Disord. 2015 May 13. doi: 10.1002/mds.26258.
    PubMed     Text format    


  471. NOYCE AJ, Mencacci NE, Schrag A, Bestwick JP, et al
    Web-based assessment of Parkinson's prodromal markers identifies GBA variants.
    Mov Disord. 2015 May 13. doi: 10.1002/mds.26249.
    PubMed     Text format    


    April 2015
  472. ERRO R
    VPS35 and EIF4G1 interactions and novel candidate genes for PD: from genes to pathways and back.
    Mov Disord. 2015;30:499.
    PubMed     Text format    


  473. FASANO A, Liu LW, Poon YY, Lang AE, et al
    Initiating intrajejunal infusion of levodopa/carbidopa intestinal gel: an outpatient model.
    Mov Disord. 2015;30:598-9.
    PubMed     Text format    


  474. NUTT JG
    Continuous levodopa infusion is better-for now.
    Mov Disord. 2015;30:443-5.
    PubMed     Text format    


  475. POEWE W, Hauser RA, Lang A
    Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.
    Mov Disord. 2015;30:589-92.
    PubMed     Text format     Abstract available


    March 2015
  476. BLANCHET PJ, Pourcher E
    In memoriam: Paul J. Bedard, MD PhD: January 19, 1942-December 26, 2014.
    Mov Disord. 2015;30:299-300.
    PubMed     Text format    


  477. ZAVALA B, Zaghloul K, Brown P
    The subthalamic nucleus, oscillations, and conflict.
    Mov Disord. 2015;30:328-38.
    PubMed     Text format     Abstract available


  478. GOLDMAN JG, Holden S, Ouyang B, Bernard B, et al
    Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests?
    Mov Disord. 2015;30:402-6.
    PubMed     Text format     Abstract available


    February 2015
  479. WEST AB
    Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.
    Mov Disord. 2015;30:180-9.
    PubMed     Text format     Abstract available


  480. SHARP ME, Caccappolo E, Mejia-Santana H, Tang MX, et al
    The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.
    Mov Disord. 2015;30:278-83.
    PubMed     Text format     Abstract available


    January 2015
  481. BEAULIEU-BOIRE I, Lang AE
    Behavioral effects of levodopa.
    Mov Disord. 2015;30:90-102.
    PubMed     Text format     Abstract available


  482. AQUINO CC, Fox SH
    Clinical spectrum of levodopa-induced complications.
    Mov Disord. 2015;30:80-9.
    PubMed     Text format     Abstract available


  483. LEES AJ, Tolosa E, Olanow CW
    Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Mov Disord. 2015;30:19-36.
    PubMed     Text format     Abstract available


  484. POEWE W, Antonini A
    Novel formulations and modes of delivery of levodopa.
    Mov Disord. 2015;30:114-20.
    PubMed     Text format     Abstract available


  485. MOSHAROV EV, Borgkvist A, Sulzer D
    Presynaptic effects of levodopa and their possible role in dyskinesia.
    Mov Disord. 2015;30:45-53.
    PubMed     Text format     Abstract available


  486. GERSHANIK OS
    Improving L-dopa therapy: the development of enzyme inhibitors.
    Mov Disord. 2015;30:103-13.
    PubMed     Text format     Abstract available


  487. KO JH, Lerner RP, Eidelberg D
    Effects of levodopa on regional cerebral metabolism and blood flow.
    Mov Disord. 2015;30:54-63.
    PubMed     Text format     Abstract available


    December 2014
  488. BOLITHO SJ, Grunstein RR, Naismith SL, Melehan K, et al
    Reply: unified techniques are needed to diagnose REM sleep behavior disorder.
    Mov Disord. 2014;29:1836.
    PubMed     Text format    


  489. FANTINI ML, Figorilli M, Ferri R
    Rapid eye movement atonia is not rapid eye movement sleep behavior disorder.
    Mov Disord. 2014;29:1835.
    PubMed     Text format    


    September 2014
  490. YAMAKADO H
    Advance in PD research explored a new field on ubiquitin biology.
    Mov Disord. 2014;29:1243.
    PubMed     Text format    


  491. MONTGOMERY E, He H
    The FM/AM world is shaping the future of deep brain stimulation.
    Mov Disord. 2014;29:1327.
    PubMed     Text format    


  492. CHIASSERINI D, Persichetti E, Paciotti S, Beccari T, et al
    Lysosomal enzymes in PD: further evidence is needed.
    Mov Disord. 2014;29:1329.
    PubMed     Text format    


  493. FASANO A, Lozano AM
    Reply: the FM/AM world is shaping the future of deep brain stimulation.
    Mov Disord. 2014;29:1327-8.
    PubMed     Text format    


  494. CHEN H, Huang X, Guo X, Peddada S, et al
    Individual and joint prevalence of three nonmotor symptoms of PD in the US general population.
    Mov Disord. 2014;29:1316-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: